13th Conference of the
International Society of Travel Medicine

Maastricht, The Netherlands
Maastricht Exhibition and Conference Centre (MECC)

19-23 May 2013

CISTM13 Program Book
Sanofi Pasteur MSD's commitment

- Develop innovative vaccines for people across Europe.
- Protect all age groups with a highly effective range of vaccines.
- Convey the unique characteristics of vaccines and their value for health.

www.spmsd.com
# Table of Contents

**Welcome Letters** ................................................................. 3  
ISTM President and CISTM13 LOC Chair ............................... 3  
CISTM13 Scientific Program Committee Chairs.................... 5  

**Organisation** ........................................................................ 7  
CISTM13 Scientific Program Committee ............................... 7  
CISTM13 Local Organizing Committee .................................. 7  
CISTM13 Oversight Committee ............................................... 8  
ISTM Executive Board ............................................................. 8  

**Sponsors and Exhibitors** ..................................................... 11  

**Descriptions of Scientific Program Sessions** ...................... 13  

**Important Information** ..................................................... 15  
Admittance Badges ................................................................. 15  
Photographs ............................................................................. 15  
Speaker Abstracts .................................................................... 15  
Wi-Fi Access at the MECC ....................................................... 15  
Liability .................................................................................... 15  
Evaluation Form ...................................................................... 16  
Continuing Medical Education (CME) Credits ..................... 16  
Continuing Education Credits for Nurses ............................ 16  
Accreditation Certificates ....................................................... 16  
Faculty Disclosures ................................................................ 17  
ISTM Charity Donations Program ......................................... 18  
Speaker Ready Room .............................................................. 19  
Welcome Reception ................................................................. 19  
Dinner at LaCaverne de Geulhem ......................................... 19  
Pre CISTM Courses ............................................................... 20  
CISTM13 Onsite Registration Information ............................ 20
Welcome to the CISTM13 at the Maastricht Exhibition and Conference Centre in Maastricht, The Netherlands!

From the ISTM President and CISTM13 Local Organizing Committee Chair

On behalf of the International Society of Travel Medicine and the Local Organizing Committee, we are pleased to welcome you to Maastricht, The Netherlands for the 13th Conference of the International Society of Travel Medicine (CISTM13). We hope you will enjoy visiting Maastricht, a wonderful place to spend time exploring its magnificent buildings, lovely cathedrals and spectacularly cobblestoned town centre. The city is well known for its fine cuisine, excellent shops and multicultural atmosphere. Maastricht is also very compact, and so everything is walking distance, or why not hire a bicycle to get around!

ISTM has now grown to 3,000 members in 90 countries and is the largest organization of professionals dedicated to the advancement of the specialty of travel medicine. Our CISTMs are really outstanding opportunities that occur only every 2 years and allow travel medicine practitioners from around the world to come together to share experiences, enjoy a collegial environment, and do a bit of travelling themselves.

We wish to take this opportunity to thank all of the participating presenters, chairs, Scientific Program Committee and Local Organising Committee members, whose hard work has produced a truly thought-provoking and dynamic programme. These conferences are now established as the leading venue for the practice and science of the discipline of travel medicine, and this is reflected in the outstanding caliber of international experts in the field who will be sharing their knowledge and experience with us over the next few days. From comprehensive review of the basic
foundations of travel medicine, through to original scientific research and new information on disease outbreaks and emerging global health issues, there should be something to benefit all attendees.

We also hope this conference will provide an opportunity for you to become more involved in the ISTM. One way of doing this is for members to attend the ISTM Membership Assembly on Wednesday, 22 May at 17.15, followed by a cocktail reception. During the Assembly you will hear more about the ISTM activities and meet the newly elected ISTM Executive Board. New ISTM members are particularly welcome to attend this session.

Also during the conference, look out for the scheduled membership meetings hosted by each of the ISTM Interest and Professional Groups. Whilst of particular interest to members of these groups, delegates wishing to attend in order to become more actively involved are also very welcome.

ISTM leaders can be identified by ribbons on their delegate badges and will be delighted to answer any questions you have regarding the society and activities of the ISTM. In addition, we encourage you to visit the ISTM booth in the exhibition hall to find out about benefits of membership, society activities, resources, literature and upcoming meetings.

We also wish to thank the sponsors and exhibitors who are participating in the CISTM. Please be sure to take the time to visit their stands in the exhibition. They will be available during the breaks in the scientific program from Monday through Wednesday.

We are certain Maastricht will provide the perfect setting for the kind of friendly and intimate ISTM meeting we all love, and are delighted that you are here to share it with us.

Cheers,

Fiona Genasi, United Kingdom
ISTM President

&

Gerard JB Sonder, The Netherlands
CISTM13 Local Organizing Committee Chair
From the Chairs of the CISTM13 Scientific Program Committee

Dear Colleagues,

On behalf of the Scientific Program Committee (SPC), we would like to welcome you to the CISTM13 where you will be treated to a stimulating scientific program and can enjoy the many activities and rich history that this wonderful city of Maastricht has to offer. The ISTM has chosen a conveniently located state-of-the-art facility for the conference and has assembled an exciting array of extra-curricular activities. We are fortunate to have confirmed many outstanding and experienced speakers from Europe and around the world who will provide you with the most important and current material in the discipline of travel medicine. The SPC began planning CISTM13 immediately after the meeting wrapped up in Boston. We met for the first time in early 2012 in Maastricht to begin working on the scientific program. We have tried to develop a program that will be exciting and stimulating for all members of our Society with presentations that will cover the latest cutting-edge information in travel medicine as well as topics and clinical challenges that travel medicine practitioners encounter in day-to-day practice.

To develop this program we have carefully considered the feedback from ISTM members from the past CISTM meetings and the suggestions for the different CISTM13 sessions, and have worked to create a rich, diverse program that will be delivered by leading experts in the field. The response to our invitations to present at the conference has been extremely positive.

In a second meeting in Guatemala in February 2013, we had to choose from amongst a record number (over 260) of original abstract submissions the ones that would be presented as oral communications. We would like to acknowledge the hard work
of participants who submitted well-designed and creative original content. The high number and quality of the abstracts submitted, each of which was carefully read and assessed by six members of the Scientific Program Committee, resulted in adding another free communication session to the program to accommodate the excellent work. Most of the other abstracts will be presented as posters during the conference, thus providing a wide range of innovative work from around the globe.

We thank our colleagues on the SPC who contributed excellent ideas and submitted proposals for sessions and then spent many hours working closely with us to evaluate the submitted abstracts in a transparent manner. Their input contributed to the breadth and richness of the topics and content of the plenaries, symposia and workshops chosen. We extend a special thanks to all members of the Society who contributed suggestions for the different sessions. We have tried to balance the selection of topics for this conference, emphasizing new ideas while providing ample coverage of general topics that – we are sure – you would like to hear the latest news about.

The membership provides inspiration for the work of the SPC. Your contributions and thoughts enrich the Society. CISTM13 provides an opportunity for travel medicine providers to reconnect with longtime colleagues, make new contacts, exchange ideas, discuss controversial topics and, not the least, to enjoy these days and have fun. We look forward to an exciting and thought-provoking conference as we strive to improve the practice of Travel Medicine and expand and solidify its scientific base. Welcome to Maastricht!

Cheers,

Mary E. Wilson, United States of America  
CISTM13 SPC Chair

Leo G. Visser, The Netherlands  
CISTM13 SPC Co-Chair

Blaise Genton, Switzerland  
CISTM13 SPC Associate Chair

Christina Greenaway, Canada  
CISTM13 SPC Associate Chair
Organisation

The ISTM greatly appreciates the contributions of time and expertise provided by the following people to the 13th Conference of the International Society of Travel Medicine.

CISTM13 Scientific Program Committee
Chair: Mary E. Wilson, Washington, DC, United States
Co-Chair: Leo G. Visser, Leiden, The Netherlands
Associate Chairs: Blaise Genton, Lausanne, Switzerland
Christina Greenaway, Montreal, Quebec, Canada
Members: Elizabeth D. Barnett, Boston, MA, United States
Michele Barry, Stanford, CA, United States
John Bosch, Terneuzen, The Netherlands
John Christenson, Indianapolis, IN, United States
Valérie D’Acremont, Basel, Switzerland
Carolyn Driver, Cheshire, England, United Kingdom
Larry Goodyer, Leicester, England, United Kingdom
Martin P. Grobusch, Amsterdam, The Netherlands
Eyal Leshem, Ramat Gan, Israel
Michael Libman, Montreal, Quebec, Canada
Poh Lian Lim, Singapore
Anne McCarthy, Ottawa, Ontario, Canada
Marc Mendelson, Cape Town, South Africa
Philippe Parola, Marseille, France
Watcharapong Piyaphanee, Bangkok, Thailand
Edward T. Ryan, Boston, MA, United States
Nohoko Sato, Tokyo, Japan
Marc Shaw, Auckland, New Zealand
Heli Siikamaki, Helsinski, Finland
Hilary Simons, Liverpool, England, United Kingdom
William Stauffer, St. Paul, MN, United States
Perry J.J. van Genderen, Rotterdam, The Netherlands

CISTM13 Local Organizing Committee
Chair: Gerard JB Sonder, Amsterdam, The Netherlands
Members: Peter de Beer, Maastricht, The Netherlands
John Bosch, Terneuzen, The Netherlands
Steven Callens, Gent, Belgium
Perry van Genderen, Rotterdam, The Netherlands
Alfons Van Gompel, Antwerpen, Belgium
Christian Hoebe, Maastricht, The Netherlands
Michiel Laaper, Sittard, The Netherlands
Yves Van Laethem, Brussels, Belgium
Philippe Leonard, Luik, Belgium
Pieter van Thiel, Amsterdam, The Netherlands
CISTM13 Oversight Committee

Chair:  
Fiona Genasi, United Kingdom  
David O. Freedman, United States of America  
Alan J. Magill, United States of America  
Gerard JB Sonder, The Netherlands  
Frank von Sonnenburg, Germany  
Diane L. Nickolson, United States of America

ISTM Executive Board

President:  
Fiona Genasi, United Kingdom  
David R. Shlim, United States of America

President-Elect:  
Alan J. Magill, United States of America

Past-President:  
Francesco Castelli, Italy  
Lin H. Chen, United States of America  
Karin Leder, Australia

Counselors:  
Annelies Wilder-Smith, Singapore

Secretary/Treasurer:  
David O. Freedman, United States of America

Executive Director:  
Diane L. Nickolson, United States of America

ISTM Executive Board from left to right.  
Back row: Annelies Wilder-Smith, Alan Magill, David Shlim, David Freedman  
Front row: Karin Leder, Diane Nickolson, Fiona Genasi, Lin Chen, Francesco Castelli
The International Society of Travel Medicine (ISTM) is committed to the promotion of healthy and safe travel. In cooperation with health care providers, academic centers, the travel industry and the media, ISTM advocates and facilitates education, service, and research activities in the field of travel medicine. This includes: preventive and curative medicine within many specialties such as tropical medicine, infectious diseases, high altitude physiology, travel related obstetrics, psychiatry, occupational health, military and migration medicine, and environmental health.

ISTM’s specific goals are to:

✓ promote travel health
✓ develop guidelines for travel medicine practice
✓ educate health care professionals, public health professionals, and the travel industry
✓ provide a scientific focus for travel medicine
✓ stimulate the professional advancement of travel medicine practice
✓ promote distribution of rapid information exchange related to travel medicine issues
✓ facilitate international contacts between practitioners of travel medicine
✓ promote development and evaluation of safe, effective, preventive and curative interventions
✓ foster research in travel medicine, including the promotion of international collaborative studies
The International Society of Travel Medicine Member Benefits Include...
The International Society of Travel Medicine would like to thank our supporters:

Exhibitors

Bimuno®
Centers for Disease Control & Prevention
Crucell
GlaxoSmithKline Vaccines registered as GlaxoSmithKline Biologicals
inFact UK Ltd
International SOS
NECTM
Novartis Vaccines & Diagnostics, Inc.
Oxford University Press
Royal College of Physicians and Surgeons of Glasgow
Sanofi Pasteur MSD
Shoreland, Inc.
Sigma-Tau S.p.A.
Sitata Inc.
South African Society of Travel Medicine (SASTM)
tropimed’
Mark your calendars for the first joint conference of the ISTM and WMS in beautiful Jackson Hole. Join us for this historic event and explore the intersection of travel and wilderness medicine.

August 3-7, 2014

Jackson Hole, Wyoming, USA
Descriptions of Scientific Program Sessions

**Plenary Lectures**
The daily plenaries during the meeting are meant to highlight areas at the forefront of travel medicine. In general these are internationally prominent invited speakers with expertise allied to travel medicine who delegates would like to hear, but who would not otherwise attend a travel medicine meeting. Each speaker is allotted 30 minutes; there is no discussion period during plenary sessions. There are no concurrent sessions running during plenaries.

**Symposium Lectures**
Each symposium is meant to highlight areas at the forefront of daily travel medicine practice. The topics are more focused than the plenaries and in many cases will appeal most to subsets of delegates with special interests. Each speaker is allotted 25 minutes for their presentation with 5 minutes for questions. Symposia are held concurrently with other sessions.

**Workshop Sessions**
Each workshop session is designed to promote dialogue between 2 experts on a topic in the field of travel medicine and individuals in practice who have experiences to share and questions to ask. While designed to be intimate and interactive, experience indicates that workshop audiences will vary. Practical information that will give participants insight into the most current strategies for prevention, self-treatment, and diagnosis is emphasized. Workshop chairs will have developed a set of clinical scenarios or case histories designed to stimulate discussion/learning. Some workshops are designated as ABC, indicating an introductory level of content, and some as Destination which focus on a particular geographic area. All workshop sessions are concurrent with other sessions.

**Debate**
The debate during the meeting is meant to highlight a controversial area at the forefront of travel medicine. This format will feature 2 highly experienced ISTM members who will debate specific issues under the broad topic. There will be opening and closing statements by each of the debaters, and time will be made available for questions from the audience to the debaters. This session will be held concurrently with other sessions.
Free Communications Oral Sessions
Each free communication session will consist of presentations of the latest original research, case studies, or experiences of travel medicine peers. Each presentation will be 10-minutes in length with 5 minutes for questions and discussion. These sessions are concurrent with other sessions.

Posters
Posters are presented on the latest original research, case studies or experiences of travel medicine practitioners. Posters must be displayed on Monday, 20 May by 10.00, and will be available for viewing from Monday, 20 May 2013 at 10.30 until Wednesday, 22 May 2013 in the Exhibit Hall. Authors will be in attendance on Wednesday, 22 May 2013 from 16.15 to 17.15.

Poster Tours
On Tuesday, 21 May 2013 during the morning and afternoon breaks, invited experts in travel medicine will lead groups to view posters and discuss selected topics. The poster tours are listed in the program schedules, and all delegates are invited to participate. To join a poster tour, simply go to the Exhibition at the start times indicated in the schedule. There will be signage placed near the entrance and Conference staff will make certain you find your selected tour leader.

Meet-the-History Lectures
In the early morning, the always popular Meet-the-History sessions describe historical and cultural background information on the local area that is of particular interest to travel medicine professionals.

Case of the Day
In an early morning session, an expert in travel medicine will present cases that are both interesting and informative to attending delegates. The cases will raise issues of diagnosis and therapy that will stimulate discussion and participation by those attending.

Meet the Professor
In these early morning sessions, travel medicine experts will meet with attendees to discuss professional development and career planning.
Important Information

Admittance Badges
Participants are required to wear their name badges while in attendance. Badges will be checked at the entrance of the exhibition and the scientific program meeting rooms. If you have misplaced your badge, registration staff will assist you in securing a replacement.

- Full Delegate Badge: All activities throughout the Conference
- One Day Badge: All activities on the specified day
- Accompanying Person Badge: Welcome Reception and Exhibition
- Persons not wearing a badge will be denied admission.

Photographs
Taking pictures of presenters and slides of the presentations is strictly prohibited. Only the ISTM contracted photographer may take photographs in the scientific program meeting rooms.

Speaker Abstracts
Abstracts from invited speakers, free communication and poster presenters can be found on the ISTM website at www.ISTM.org for all delegates to review and download. Once on the website click on the CISTM13 picture on the home page to access the full CISTM13 website. The link to the abstracts can be found in the navigation column on the left side of this page.

Wi-Fi Access at the Maastricht Exhibition and Conference Centre (MECC)
ISTM is delighted to be providing Wi-Fi access in the MECC free to all CISTM13 delegates. To log in, use ‘CISTM13’ as both your username and password when prompted.

Liability
The 13th Conference of the International Society of Travel Medicine in no event shall be liable for acts or defaults in the event of injury, damage, loss, accident, delay or irregularity of any kind whatsoever during arrangements organized through contractors or the employees of such contractors in performing services. The organizers reserve the right to make changes, where deemed necessary, without prior notice to parties concerned.
**Evaluation Form**
You will find an evaluation form in your conference bag. Please take a few minutes to evaluate the sessions you attend. The form can be returned to the Registration Desk.

**Continuing Medical Education (CME) Credits**
The ‘13th Conference of the International Society of Travel Medicine’ is designated for a maximum of (or ‘for up to’) 20 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits”. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

**EACCME credits**
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

**Continuing Education Credits for Nurses**
The Dutch Accreditation Committee grants as standard 3 accreditation points per day of attendance at CISTM13. For nurses who attend the conference on Tuesday May 21, 3 extra accreditation points will be requested to make a total of 6 points.

Accreditation for the CISTM13 is currently being sought from the American Association of Nurse Practitioners (AANP). This program is pending AANP approval at the time of printing these materials.

**Accreditation Certificates**
If your registration included CME or CE accreditation you should have received these materials with your registration. Please check with the registration staff if you have any questions.
Faculty Disclosures

Jesse Alves  
Antoine Andremont 1  
Helena Hervius Askling 2  
Satchit Balsari  
Elizabeth D. Barnett 3  
Buddha Basnyat  
Quique Bassat 4  
Trish Batchelor 5  
Irmgard Bauer  
Ron H. Behrens 6  
Johannes Blum  
Andrea K. Boggild  
Sarah Borwein  
John Bosch  
Emmanuel Bottieau  
Benjamin Brenner  
Gerd Burchard 7  
Corrie C. Brown  
I. Dale Carroll  
Francesco Castelli  
Eric Caumes 8  
Martin Cetron  
Lin H. Chen 9  
Jane Chiodini 10  
Joannes Clerinx  
Kerrynn Cope  
Roel Coutinho  
Valérie D’Acremont  
V.A.S.H. Dalm  
Philippe Gautret  
Mark Gershman  
Jeff Goad 11  
Larry Goodyer 12  
Martin P. Grobusch  
Stefan Hagmann  
Sheila C. K. Hall  
David Hamer 13  
Randi Hammer Boge  
Stephen W. Hargarten  
Christoph Hatz 14  
Karl M. Hess 15  
David L. Heymann  
David R. Hill  
Li Yang Hsu 16  
Nancy Piper Jenks  
Emily S. Jentes  
Michael E. Jones 17  
Susan R. Kahn  
Kevin Kain  
Jay Keystone  
Susan Kuhn  
Ted Lankester  
Karim Leder 18  
Peter A. Leggat 19  
Eyal Leshem  
Claudine Leuthold  
Michael Libman 20  
Poh Lian Lim  
Alan J. Magill  
Alberto Matteelli  
Anne McCarthy  
Brian McCloskey  
Marc Mendelson  
Deborah Mills 21  
Margot Mütsch  
Abdisalan Mohamed Noor  
Cecilia Perret 22  
Watcharapong Piyaphanee  
Peter M. Rabinowitz  
Jan Hindrik Ravseloot  
Julie Richards  
Gail Rosselot  
Robert Sack  
Patricia Schlagenhauf 23  
Brian S. Schwartz  
Eli Schwartz  
Kevin Schwartzman  
Mary-Louise Scully  
Marc Shaw  
David R. Shlim  
Hilary Simons  
Gerard JB Sonder  
Darius Soonawala  
Mike Starr  
Robert Steffen  
Perry van Genderen 24  
Lisette van Lieshout  
Christopher Van Tilburg  
Timothy Walsh  
Brian Ward 25  
Jim Waterhouse  
Annelies Wilder-Smith  
Caroline S. Zeind  
Irina V. Zhdanova 26

The footnoted Speakers have indicated that they have relationships with the entries listed below which, in the context of their presentations(s), could be perceived as a potential conflict of interest (e.g., direct research funding from a commercial organization, etc.).

1. Da Volterra Company – Honorarium; Genewave – collaboration with French National Agency for Innovation
2. Abbott – Honorarium for vaccine biologics; Intercell – investigator JE Vaccine; Sanoﬁ Pasteur MSD- investigator pediatric MMR
3. Intercell – research funding; Cerexa – research funding, travel; Novartis – honorarium
4. Novartis – travel; Sigma Tau – travel and honorarium
5. GlaxoSmithKline – honorarium, speaker malaria
ISTM Charity Donations Program

Thank you to those who have already donated to this program. It is not too late to participate in this opportunity to enhance your ability to assist the less fortunate throughout the world. For that purpose, the ISTM intends to equally match the amount donated by CISTM13 delegates to any of the charitable organizations listed below, up to an aggregate maximum ISTM contribution (for all the charities) of USD 15,000 (approximately 11,500 Euro). The eligible organizations, which focus on helping people in poorer communities in specified regions of the world, were selected based on recommendations by ISTM members. ISTM believes that each serves worthy goals, but has not conducted any detailed investigation of their operations, and is not specifically recommending or endorsing any of these organizations. You can learn about each of these organizations by visiting its website (also listed below), or making such other inquiry as you believe appropriate. The eligible organizations are:

Australian Himalayan Foundation, based in Australia serving Nepal
www.australianhimalayanfoundation.org.au

Chad Relief Foundation, based in the United States of America serving Chad
www.chadrelief.org
Mae Tao Clinic, partner with Community Partners International in the United States of America based in Burma, serving Burma
www.maetaoclinic.org

Neary Khmer, based in Cambodia serving Cambodia
www.nearykhmer.org

Vine Trust, based in Scotland serving Peru and Tanzania
www.vinetrust.org/home

ISTM makes no representations as to deductibility or other legal or tax consequences of any CISTM13 registrant’s contributions to these organizations, since such matters are determined by the laws of both the recipient’s location and the donor’s place of tax residency, as well as the donor’s personal tax and financial circumstances. Each potential donor is advised to consult with his or her financial and tax advisers to determine the consequences to him or her of such a donation.

**Speaker Ready Room**
The Speaker Ready Room is located at the MECC in The Madrid Room, Level 0, Room 0.6. The Speaker Ready Room hours are:

- **Sunday, 19 May 2013:** 08.00-17.00
- **Monday, 20 May 2013:** 07.00-17.00
- **Tuesday, 21 May 2013:** 07.00-17.00
- **Wednesday, 22 May 2013:** 07.00-16.00
- **Thursday, 23 May 2013:** 07.00-11.00

Speakers can bring files on CD-Rom or a Memory Stick for uploading into the onsite audiovisual equipment. We ask that all speakers bring their presentations to the speaker ready room the day before their scheduled session, but no later than two hours prior to their scheduled session.

**Welcome Reception**
The Welcome Reception will take place immediately following the Opening Ceremony on Sunday, 19 May 2013 at the Exhibition located on the first level of the MECC, in the Expo Foyer from 18.00 – 20.00.

**Dinner at La Caverne de Geulhem**
The optional dinner has been sold out. If your registration included tickets to this dinner, you would have received them, with information regarding the shuttle service, with your registration materials. If you have any questions, please consult staff at the registration desk.
Pre CISTM Courses
The two pre-CISTM courses are being held on Sunday, 19 May from 14.00 to 16.30 at the MECC. If you registered for one of the courses, you would have received your admittance tickets when you registered. If you have any questions, please consult staff at the registration desk.

CISTM13 Onsite Registration Information
The Registration Desk is located in the Trajectum area of the MECC. Registration hours are as follows:

- Saturday, 18 May 2013: 18.00-20.00
- Sunday, 19 May 2013: 10.00-20.00
- Monday, 20 May 2013: 07.00-17.00
- Tuesday, 21 May 2013: 08.00-17.00
- Wednesday, 22 May 2013: 08.00-17.00
- Thursday, 23 May 2013: 08.00-14.00

International SOS
Medical Opportunities for Doctors

International SOS is the world’s leading provider of global medical assistance, international healthcare and security services. We have a range of opportunities including permanent residential positions in large cities or exciting opportunities in remote operational sites.

Remote Site Medical Services working with global oil, gas, mining and energy corporations in assessing the health risks of their onsite employees working in remote operational environments across Asia, Africa, Australasia and Middle East.

Global Medical Assistance
Our assistance centres are staffed by qualified medical professionals who respond to calls for assistance in the event of a medical emergency - evacuation and repatriation.

International SOS Clinics
Our clinics operate in countries where medical care of an international standard is unavailable. Our clinics offer our local and expatriate members a range of primary care, diagnostic and emergency care within a general practice setting.

To join us
To find out more information regarding the above international opportunities & to apply online go to our website at www.internationalsos.com and follow the link to the “International Medical Career Opportunities” section.
Maps of Maastricht Exhibition and Conference Centre

Plattegrond MECC Maastricht
Plattegrond MECC Maastricht
The 14th Conference of the International Society of Travel Medicine

24-28 May 2015

Québec City, Canada

International Society of Travel Medicine
Promoting healthy travel worldwide

www.ISTM.org

Early Registration: 31 December 2014
Abstract Submission: 7 January 2015
CISTM13 Opening Ceremony

Auditon, MECC

19 May 2013
17.00-18.00

Chairs: Fiona Genasi, President of the ISTM
Gerard JB Sonder, CISTM13 Local Organizing Committee Chair

17.00-17.05 | Welcome to the CISTM13
Fiona Genasi, ISTM President

17.05-17.10 | Welcome to the Netherlands and Belgium
Gerard JB Sonder, Chair LOC

17.10-17.20 | Welcome to Maastricht
Theo Bovens, King’s Commissioner for the Province of Limburg

17.20-17.35 | Entertainment
De Nachtwacht

17.35-17.40 | The CISTM13 Scientific Program
Mary E. Wilson, CISTM13 Scientific Program Committee Chair

17.40-18.00 | Keynote Speaker
David Overbosch: Infectious Diseases and Art

18.00-18.05 | Closing Remarks
Gerard JB Sonder, CISTM13 LOC Chair

Immediately following the Opening Ceremony the Welcome Reception will be held in the Expo Foyer of the MECC.
Welcome to Maastricht!
# CISTM13 Program Schedule

All sessions held in the Maastricht Exhibition and Conference Centre (MECC).

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sunday 19 May 2013</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-16.30</td>
<td><strong>Pre CISTM Course 1</strong>&lt;br&gt;Psychological Issues in International Travel: All you Need to Know</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td></td>
<td><strong>Pre CISTM Course 2</strong>&lt;br&gt;Responsible Travel: A Travel Health Concern?</td>
<td>Rome, Level 0 Room 0.8</td>
</tr>
<tr>
<td>15.00-16.30</td>
<td><strong>Nurses Reception</strong></td>
<td>Brussels/Paris, Level 0 Rooms 0.4/0.5</td>
</tr>
<tr>
<td>15.00-16.30</td>
<td><strong>Pharmacists Reception</strong></td>
<td>Pressroom, Level 0 Room 0.11</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td><strong>Opening Ceremony</strong></td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td>18.00-20.00</td>
<td><strong>Welcome Reception</strong></td>
<td>Exhibition, Level 1</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>MTH1</td>
<td>Meet The History 1</td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>From House of God to Academic Hospital: The History of Medicine in Maastricht</td>
<td></td>
</tr>
<tr>
<td></td>
<td>H.F.P Hillen, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>COD1</td>
<td>Case of the Day 1</td>
<td>Rome, Level 0 Room 0.8</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Vanessa Field, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>MTP1</td>
<td>Meet the Professor 1</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Mentorship</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michele Barry, United States of America</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td></td>
<td><strong>Monday 20 May 2013, continued</strong></td>
<td></td>
</tr>
<tr>
<td>PL1</td>
<td><strong>Plenary 1</strong></td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>Antibiotic Resistance: Mobile Bugs in a Connected World</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Leo G. Visser, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mary E. Wilson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL1.1 Overview, Mechanisms, Example of Delhi NDM1 Spread</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Timothy Walsh,</strong> United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand three ways bacteria can become resistant to antibiotics,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and how the movement of genetic elements confers resistance among</td>
<td></td>
</tr>
<tr>
<td></td>
<td>bacteria.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn two factors that have enabled the spread of bacteria with</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NDM-1.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL1.2 Travelling Golden Staphylococci</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Li Yang Hsu,</strong> Singapore</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand three consequences of staphylococcal infections by</td>
<td></td>
</tr>
<tr>
<td></td>
<td>travellers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn the role of travellers in the movement of staphylococci and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>resistance elements across populations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn the drivers of resistance, including the use of antimicrobials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in animals.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL1.3 Acquisition, Colonization and Spread by Unsuspecting Travellers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Antoine Andremont,</strong> France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the three ways to reduce the development and spread of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>resistant bacteria.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand the ecology of resistance.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn the identification, monitoring, and control of resistance.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn about the persistence and movement of elements conferring</td>
<td></td>
</tr>
<tr>
<td></td>
<td>resistance in colonizing bacteria.</td>
<td></td>
</tr>
<tr>
<td>10.30-11.15</td>
<td><strong>Morning Break</strong></td>
<td>Exhibition, Level 1</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>SY1</td>
<td><strong>Symposium 1</strong></td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td><em>Jet Lag Chronobiology, Travel and Treatment</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Lin H. Chen, United States of America</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Louis Loutan, Switzerland</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY1.1 The Circadian Clock and Time Zone Travel</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Irina V. Zhdanova, United States of America</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review circadian system and how it responds to time</td>
<td></td>
</tr>
<tr>
<td></td>
<td>shift.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review why we develop jet lag syndrome and how it</td>
<td></td>
</tr>
<tr>
<td></td>
<td>differs from other forms of desynchrony.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY1.2 Maximizing Performance Across Time Zones</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Jim Waterhouse, United Kingdom</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review pros and cons of light therapy, behaviour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>modifications, diet and exercise, napping and other</td>
<td></td>
</tr>
<tr>
<td></td>
<td>actions that individual travellers could initiate as</td>
<td></td>
</tr>
<tr>
<td></td>
<td>non-pharmacologic interventions.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY1.3 Pharmacotherapy</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Robert Sack, United States of America</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review evidence that various pharmacologic agents</td>
<td></td>
</tr>
<tr>
<td></td>
<td>work for jet lag syndrome.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review pros and cons of melatonin, caffeine,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hypnotics.</td>
<td></td>
</tr>
<tr>
<td>FC1</td>
<td><strong>Free Communication 1</strong></td>
<td>Paris, Level 0, Room 0.5</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td><em>All About Malaria</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Jeff Goad, United States of America</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Pieter van Theil, The Netherlands</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>FC1.1 Malaria Knowledge and Use of Malaria Prevention</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>in the UK Population and in UK Passengers Departing to</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Malaria Endemic Areas.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Ron H. Behrens, United Kingdom</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>FC1.2 Eye Disorders Reported with the Use of Mefloquine</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chemoprophylaxis – a Drug Safety Database Analysis</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Patricia Schlagenhaus, Switzerland</em></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
</tbody>
</table>
| 11.45-12.00 | **FC1.3** Acute Malaria Infections Despite a Complete or Abbreviated Chemoprophylactic Regimen of Atovaquone-Proguanil  
Paul M. Arguin, United States of America |                 |
| 12.00-12.15 | **FC1.4** How did Travellers Use During their Trip Rapid Diagnostic Test for Malaria Provided by a Travel-clinic?  
Delphine Berthod, Switzerland |                 |
| 12.15-12.30 | **FC1.5** Artemether-Lumefantrine Compared to Atovaquone-Proguanil as a Treatment for Plasmodium falciparum Malaria in Travelers  
Tamar Lachish, Israel |                 |
| 12.30-12.45 | **FC1.6** Safety of Antimalarials in the Treatment of Severe Imported Malaria - a Single-centre Retrospective Study.  
Thierry Rolling, Germany |                 |
| WS1        | 11.15-12.45 **Workshop 1** Would You Vaccinate this Traveller: Yellow Fever Vaccine Cases  
Mark Gershman, United States of America  
Christoph Hatz, Switzerland  
- 3-4 case studies will be discussed and essential criteria to consider in deciding on the appropriateness of prescribing yellow fever vaccination will be highlighted. Case studies will address yellow fever vaccination recommendations and country entry requirements, as well as medical contraindications and precautions to vaccination. | Rome, Level 0 Room 0.8 |
**Symposium 2**

**One World: Migrants and Health**

*Chairs: Francesco Castelli, Italy*

*Jose Flores-Figueroa, Mexico*

**SY2.1 BioMosaic**

*Martin Cetron, United States of America*

- Review the magnitude and growth of global migration and its impact on human health.
- Describe The BioMosaic Project and present its objectives and application to public health and travel medicine.

**SY2.2 Accessing VFR Populations for Public Health Messages**

*Peter A. Leggat, Australia*

- Review the travel health risks related to VFR travel.
- Describe novel approaches to engaging immigrant communities to access and promote pre-travel advice in the VFR population.

**SY2.3 Approach to Migrants Upon Arrival**

*Anne McCarthy, Canada*

- Review the health status of migrants and predictors for poor health outcomes.
- Present an overview of the recently published Canadian Collaboration for Immigrant and Refugee Health (CCIRH) guidelines as an example of an approach to health promotion post-arrival and describe applications of this to travel health.
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS2</td>
<td>Workshop 2</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td>The Anticoagulated Traveller: Issues and Answers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael Libman, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Susan Kahn, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Perry van Genderen, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the risk and associated challenges of travel while taking</td>
<td></td>
</tr>
<tr>
<td></td>
<td>anticoagulants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss practical strategies of how to manage anticoagulation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>medications during travel including adjusting doses, avoid drug</td>
<td></td>
</tr>
<tr>
<td></td>
<td>interactions, etc.</td>
<td></td>
</tr>
<tr>
<td>12.45-14.45</td>
<td>Lunch Break</td>
<td>Exhibition, Level 1</td>
</tr>
<tr>
<td>SY3</td>
<td>Symposium 3</td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td>Risk: Perceived vs. Real, and Communication Tools</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Charles D. Ericsson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Annelies Wilder-Smith, Singapore</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SY3.1 Perceived versus Actual Risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ron H. Behrens, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review estimated risk for different diseases and different destination</td>
<td></td>
</tr>
<tr>
<td></td>
<td>according to travel information.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the perceived risk for the same diseases and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>destination.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain the reasons for these differences.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SY3.2 Helping the Professional Understand Risk Concepts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Karin Leder, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the determinants of risk and how it is calculated.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the pitfalls to estimate risk in travel medicine.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Give examples on how health professionals can better understand risk.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SY3.3 Helping the Professional Communicate Risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jane Chiodini, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how actual risk can be appropriately communicated to a lay</td>
<td></td>
</tr>
<tr>
<td></td>
<td>person and give examples.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Illustrate how different means can lead to different</td>
<td></td>
</tr>
<tr>
<td></td>
<td>uptake of preventive measures.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>SY4</td>
<td><strong>Symposium 4</strong>&lt;br&gt;New and Emerging Bugs and Travel: Tryps, TB, and Fungi&lt;br&gt;<strong>Chairs:</strong> Christoph Hatz, Switzerland&lt;br&gt;Shuzo Kanagawa, Japan</td>
<td>Brussels, Level 0 Room 0.4</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>SY4.1</strong> Trypanosomiasis&lt;br&gt;Joannes Clerinx, Belgium&lt;br&gt;• Review briefly the epidemiology, clinical manifestations and diagnostic criteria for trypanosomiasis.&lt;br&gt;• Illustrate by the description of cases of imported trypanosomiasis and why it has been (or not been) suspected.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY4.2</strong> MDR, XDR, TDR-TB&lt;br&gt;Martin P. Grobusch, The Netherlands&lt;br&gt;• Review briefly the epidemiology, risk factors and criteria to diagnose MDR, XDR, TDR-TB.&lt;br&gt;• Describe the different therapies available and their effectiveness.&lt;br&gt;• Assess the risk for the traveller.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY4.3</strong> Fungal Infections in Travellers&lt;br&gt;Eli Schwartz, Israel&lt;br&gt;• Review briefly the epidemiology, risk factors and procedures to diagnose the most prevalent.&lt;br&gt;• Give some examples of these with pictures and review the treatment.</td>
<td></td>
</tr>
<tr>
<td>WS3</td>
<td><strong>Workshop 3</strong>&lt;br&gt;High Altitude Travel&lt;br&gt;Buddha Basnyat, Nepal&lt;br&gt;Alan J. Magill, United States of America&lt;br&gt;• Discuss health problems at high altitude and pathophysiology.&lt;br&gt;• Discuss pharmacological and behavioural interventions.&lt;br&gt;• Discuss high risk travellers and itineraries.</td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>WS4 14.45-16.15</td>
<td><strong>Workshop 4</strong>&lt;br&gt;Seeking Answers: Resources for Travel Medicine (ABC)  &lt;br&gt;<strong>David Hamer,</strong> United States of America  &lt;br&gt;<strong>Claudine Leuthold,</strong> Switzerland  &lt;br&gt;- Know where to find background information on country, security, maps, disability, and evacuation.  &lt;br&gt;- Use surveillance and epidemiological data.  &lt;br&gt;- Apply different sources of travel medicine recommendations.  &lt;br&gt;- Appraise travel warnings and consular information.  &lt;br&gt;- Use vaccine resources.</td>
<td><strong>Rome, Level 0 Room 0.8</strong></td>
</tr>
<tr>
<td>FC2 14.45-16.15</td>
<td><strong>Free Communication 2</strong>&lt;br&gt;Special Needs (Mental Health and Immunosuppression)  &lt;br&gt;<strong>Chairs:</strong> <strong>Michael E. Jones,</strong> United Kingdom  &lt;br&gt;<strong>Thomas Valk,</strong> United States of America</td>
<td><strong>Athens, Level 0 Room 0.9</strong></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td><strong>FC2.1</strong> Mental Health and Study Abroad: Incidence and Mitigation Strategies  &lt;br&gt;<strong>Ryan Copeland,</strong> United States of America</td>
<td></td>
</tr>
<tr>
<td>15.00-15.15</td>
<td><strong>FC2.2</strong> Japanese Encephalitis Vaccine Administration Practices Among U.S. Travel Medicine Practices in Global TravEpiNet  &lt;br&gt;<strong>Regina C. LaRocque,</strong> United States of America</td>
<td></td>
</tr>
<tr>
<td>15.15-15.30</td>
<td><strong>FC2.3</strong> The Traveling-Travel Clinic: Improving Access for Visiting Friends and Relative Travelers, Hajj Clinic Pilot Project  &lt;br&gt;<strong>Gregory Carlson,</strong> United States of America</td>
<td></td>
</tr>
<tr>
<td>15.30-15.45</td>
<td><strong>FC2.4</strong> Immune Response to Combined Hepatitis A and B Vaccine in HIV-infected Children or Children on Immunosuppressive Medication in Juvenile Idiopathic Arthritis in Contrast to Healthy Children: A Substantial Proportion Not Immune for Hepatitis A after First Vaccination  &lt;br&gt;<strong>Gerard JB Sonder,</strong> The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| 15.45-16.00| **FC2.5** International Travel Patterns and Travel Risks of Stem Cell Transplant Recipients  
Tarek Mikati, United States of America | FC2.5                  |
| 16.00-16.15| **FC2.6** Epidemiology and Treatment of Hydatid Cyst in the AMC  
Cornelis Stijnis, The Netherlands | FC2.6                  |
| 16.15-17.00| Afternoon Break                                                        | Exhibition, Level 1    |
| SY5        | **Symposium 5** Who Should be Vaccinated? Difficult Vaccine Decisions: Yellow Fever, Rabies, and Influenza  
Chairs: Marc Mendelson, South Africa  
Gary Brunette, United States of America | Auditorium, Level 1    |
| 17.00-18.30| SY5.1 Rabies  
Philippe Gautret, France  
- Review current controversies about the use of rabies vaccine.  
- Understand the pros and cons of using vaccine (or RIG or a specific dose or route) in each situation. | SY5.1                  |
|            | SY5.2 Yellow Fever  
Elizabeth D. Barnett, United States of America  
- Review the current controversies about the use of yellow fever vaccine.  
- Understand the data to support use or non-use of vaccine in each situation. | SY5.2                  |
|            | SY5.3 Influenza  
Margot Mütsch, Switzerland  
- Current controversies about use of influenza vaccine in individuals and populations. | SY5.3                  |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.00-18.30</td>
<td><strong>Panel Discussion</strong>&lt;br&gt;Filling the Gaps in the Knowledge Base: Research Priorities in Travel Medicine&lt;br&gt;<em>Chairs:</em> Michele Barry, United States of America&lt;br&gt;Ron H. Behrens, United Kingdom&lt;br&gt;<em>Panelists:</em> Nancy Piper Jenks, United States of America&lt;br&gt;Kevin Kain, Canada&lt;br&gt;Annelies Wilder-Smith, Singapore&lt;br&gt;- Each presenter will present her (his) own view on the two main gaps in knowledge in the travel medicine field and the best study design to address those.&lt;br&gt;- A discussion with presenters and audience will follow.</td>
<td>Brussels, Level 0 Room 0.4</td>
</tr>
<tr>
<td>WS5</td>
<td><strong>Workshop 5</strong>&lt;br&gt;Refresh! What’s New in Travel and Tropical Medicine Literature&lt;br&gt;<em>Gerd Burchard,</em> Germany&lt;br&gt;<em>Mary-Louise Scully,</em> United States of America&lt;br&gt;- Describe the results of new studies or observations within the past two years that affect recommendations in travel medicine.&lt;br&gt;- Explain how these new findings can be integrated into the practice of travel medicine.</td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>WS6</td>
<td><strong>Workshop 6</strong>&lt;br&gt;Safe and Intact: Safety, Security, and Injury During Travel&lt;br&gt;<em>Stephen W. Hargarten,</em> United States of America&lt;br&gt;<em>Marc Shaw,</em> New Zealand&lt;br&gt;- Review the safety, security and injury risks related to travel.&lt;br&gt;- Discuss practical strategies to decrease risk and to remain safe and secure during travel.</td>
<td>Rome, Level 0 Room 0.8</td>
</tr>
<tr>
<td>FC3</td>
<td><strong>Free Communication 3</strong>&lt;br&gt;Health Problems in Returning Travellers&lt;br&gt;<em>Kenneth Dardick,</em> United States of America&lt;br&gt;<em>Alfons van Gompel,</em> Belgium</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
</tbody>
</table>
| 17.00-17.15| **FC3.1** *Health Problems During and After Travel among Boston-Area International Travellers*  
              Lin H. Chen, United States of America                                                                                                                                  | Brussels, Level 0  |
|            | **FC3.2** *Travel Acquired Infections and Illnesses in Canadians: Surveillance Report from CanTravNet Surveillance Data, 2009—2011*                                             | Room 0.4          |
|            | Andrea K. Boggild, Canada                                                                                                                                                       |                   |
| 17.30-17.45| **FC3.3** *High Acquisition Rates of Extended Spectrum β-Lactamase Producing Enterobacteriaceae among Dutch Travelers*                                                           |                   |
|            | Jessica A. Vlot, The Netherlands                                                                                                                                               |                   |
| 17.45-18.00| **FC3.4** *The Changing Epidemiology of Human African Trypanosomiasis among Patients from Non-Endemic Countries, 1902-2012*                                                         |                   |
|            | Ami Neuberger, Israel                                                                                                                                                          |                   |
| 18.00-18.15| **FC3.5** *Acute Hepatitis in Israeli Travellers*                                                                      
              Tamar Lachish, Israel                                                                                                                                                    |                   |
| 18.15-18.30| **FC3.6** *Different Etiologies of Creeping Dermatitis in 70 Consecutive Patients*                                                                                             |                   |
|            | Eric Caumes, France                                                                                                                                                            |                   |
| 18.30-19.15| **Special Update**  
              Highlights from the New Editions, WHO and CDC  
              Gilles Poumerol, WHO, Switzerland  
              Gary Brunette, CDC, United States of America  
              Brussels, Level 0 Room 0.4                                                                                                                                             |                   |
| 18.30-19.15| **ISTM Pediatric Interest Group General Assembly**                                                                      
              Paris, Level 0 Room 0.5                                                                                                                                                    |                   |
| 18.30-19.15| **ISTM Destination Communities Support Interest Group General Assembly**                                              
              Rome, Level 0 Room 0.8                                                                                                                                                    |                   |
| 18.30-19.15| **ISTM Psychological Health of Travellers Interest Group General Assembly**                                            
              Athens, Level 0 Room 0.9                                                                                                                                                    |                   |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTH2</td>
<td>Meet the History 2</td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Malaria in Belgium, The Netherlands, and Elsewhere in Europe: A Forgotten History!</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marc Coosemans, Belgium</td>
<td></td>
</tr>
<tr>
<td>COD2</td>
<td>Case of the Day 2</td>
<td>Rome, Level 0 Room 0.8</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Prativa Pandey, Nepal</td>
<td></td>
</tr>
<tr>
<td>MTP2</td>
<td>Meet the Professor 2</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Abstract Writing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Charles D. Ericsson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anu Kantele, Finland</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td></td>
<td><strong>Tuesday, 21 May 2013, continued</strong></td>
<td></td>
</tr>
<tr>
<td>PL2</td>
<td>09.00-10.30</td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td></td>
<td><strong>Plenary 2</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Malaria: From Research to Recommendation</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Blaise Genton, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peter A. Leggat, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL2.1 Malaria Maps: Relevance for Travel Recommendations</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abdisalan Mohamed Noor, Kenya</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Description of the process to build malaria maps and the dynamics of update.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Give examples of malaria maps freely available on the internet.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discussion of which kind of malaria maps and how they could be useful to update travel recommendations (EIR, Pf prevalence etc.).</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL2.2 Artemisinin Derivatives for all Malaria</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Quique Bassat, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Description of the results of efficacy and effectiveness trials of ACT for species other than Plasmodium falciparum in endemic areas of Asia and Oceania.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discussion of the comparative advantages of the different ACT marketed in the US and Europe for species other than falciparum.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Description of the procedures in practice (including the use of primaquine.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL2.3 Diagnosis of Imported Malaria: Beyond Microscopy</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Valérie D'Acremont, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the results of meta-analyses and studies that assessed performance of RDT in endemic and non-endemic areas and explain the pitfalls in these evaluations.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Description of the safety and usefulness of RDT in non-endemic settings.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Description of the procedures for RDT selection and implementation in non-endemic settings.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>10.30-11.15</td>
<td><strong>Morning Break</strong>&lt;br&gt;<strong>Poster Tours</strong>&lt;br&gt;(Meet Tour Leaders at Entrance of Exhibition)&lt;br&gt;<strong>Enteric Infections</strong>&lt;br&gt;Edward T. Ryan, United States of America&lt;br&gt;<strong>Malaria</strong>&lt;br&gt;William Stauffer, United States of America&lt;br&gt;<strong>Pre-Travel Advice</strong>&lt;br&gt;Carolyn Driver, United Kingdom</td>
<td>Exhibition, Level 1</td>
</tr>
<tr>
<td>SY6 11.15-12.45</td>
<td><strong>Symposium 6</strong>&lt;br&gt;<strong>Immunosuppressed Travellers: Safe Preparation</strong>&lt;br&gt;Chairs: Bradley Connor, United States of America&lt;br&gt;Karin Leder, Australia&lt;br&gt;<strong>SY6.1 Standard Immunosuppressive Drugs</strong>&lt;br&gt;V.A.S.H. Dalm, The Netherlands&lt;br&gt;- Classify immunosuppressive therapies commonly used in organ transplantation according to their site of action.&lt;br&gt;- Outline the effect of immunosuppressive therapies on primary and secondary immune responses to vaccines.</td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td></td>
<td><strong>SY6.2 Biologic Agents</strong>&lt;br&gt;Helena Hervius Askling, Sweden&lt;br&gt;- Explain the effect of structure and composition of monoclonal antibodies on half life.&lt;br&gt;- Distinguish between depleting (cytotoxic) and non-depleting monoclonal antibodies.&lt;br&gt;- Predict the effect anti-TNF monoclonal antibodies on primary and secondary immune response to (travel) vaccines.&lt;br&gt;- Predict the effect of rituximab on primary and secondary immune response to (travel) vaccines.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY6.3 Immunosuppressive Disease</strong>&lt;br&gt;Brian S. Schwartz, United States of America&lt;br&gt;- Describe types of immunosuppressive diseases.&lt;br&gt;- Outline implications for susceptibility to travel-related diseases.&lt;br&gt;- Outline implication for response to vaccines (safety and effectiveness).</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
</tbody>
</table>
| SY7 11.15-12.45 | Symposium 7  
**Keeping Kids Healthy During Travel**  
*Chairs:* Philip R. Fischer, United States of America  
          Eli Schwartz, Israel  

**SY7.1 High Risk Itineraries in Under 5s (includes VFR)**  
Susan Kuhn, Canada
- Review the health risks of young infants and children travelling to high-altitude destinations, malaria-endemic regions etc.  
- Discuss the approach to and efficacy of decreasing health risks in these young travellers.

**SY7.2 Diarrhoea in Child Travellers**  
Eyal Leshem, Israel
- Discuss the epidemiology and specific risk factors for travel associated diarrhoea in young children.  
- Discuss the approach to prevention and management of diarrhoea in young children.  
- Discuss the pros and cons of empiric antibiotic use and the different choices of antibiotics in young children.

**SY7.3 Use of Newer Vaccines in Children**  
Stefan Hagmann, United States of America
- Review the epidemiology of specific travel vaccine preventable disease in young children including meningococcus, hepatitis A, yellow fever and Japanese encephalitis.  
- Review which young travellers should receive these vaccines and under what circumstances.  
- Highlight the specific challenges, limitations and controversies in providing these vaccines to young children.

| FC4 11.15-12.45 | Free Communication 4  
**Pre-Travel Practice**  
*Chairs:* Nancy Piper Jenks, United States of America  
          Joseph Torresi, Australia |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Paris, Level 0, Room 0.5</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| 11.15-11.30 | **FC4.1** Knowledge, Attitudes and Practices of U.S. Practitioners Who Provide Pre-Travel Advice: Differences between Primary Care Providers and Travel Medicine  
David Hamer, United States of America | Rome, Level 0 Room 0.8 |
| 11.30-11.45 | **FC4.2** Malaria: Are Pharmacists Sufficiently Prepared to Assess and Manage Prevention Strategies?  
Adrienne Willcox, United Kingdom | Rome, Level 0 Room 0.8 |
| 11.45-12.00 | **FC4.3** Pre-Travel Health Care of Immigrants Returning Home to Visit Friends and Relatives  
Regina C. LaRocque, United States of America | Rome, Level 0 Room 0.8 |
| 12.00-12.15 | **FC4.4** Characteristics, Preferences and Decision Needs of Travellers to Countries with Risk of Yellow Fever: Implications for Healthcare Providers  
Lin H. Chen, United States of America | Rome, Level 0 Room 0.8 |
| 12.15-12.30 | **FC4.5** Evaluation of Vaccination Coverage in Travellers to a Yellow Fever Endemic Area (Senegal) for a Stay  
Christophe Rapp, France | Rome, Level 0 Room 0.8 |
| 12.30-12.45 | **FC4.6** Malaria and Yellow Fever Prevention Advice Provided by Travel Agency Employees in Cusco – Peru  
Miguel M. Cabada, Peru | Rome, Level 0 Room 0.8 |
| WS7 11.15-12.45 | **Workshop 7** Exotic Asia: Mekong Delta/Burma (Destination)  
Trish Batchelor, Australia  
Watcharapong Piyaphanee, Thailand  
- Describe of features of the region, including environment and the people.  
- Describe the major health and security threats to travellers. | Rome, Level 0 Room 0.8 |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS8 11.15-12.45</td>
<td><strong>Workshop 8</strong>  How to Start a Travel Clinic (ABC)  &lt;br&gt; John Bosch, The Netherlands  &lt;br&gt; Gail Rosselot, United States of America  &lt;br&gt; - Review of strategic planning for travel clinic development, international differences to consider when establishing a travel clinic, suggestions for marketing, and promoting best practices in your clinic.  &lt;br&gt; - Review of text and internet resources for clinic start-up: CDC, ISTM, IAC, Dutch, other international resources and selected travel medical texts.</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td>12.45-14.45</td>
<td><strong>Lunch Break</strong></td>
<td>Exhibition</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Level 1</td>
</tr>
</tbody>
</table>
### Time Program Location

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| SY8 14.45-16.15 | Symposium 8  
Easy to Prevent But Still Here: Measles, Pertussis, Polio  
_Chairs:_ Elizabeth D. Barnett, United States of America  
Poh Lian Lim, Singapore  
SY8.1 The Spread of Measles to and from Europe and Beyond: Implications for Global Travel  
David R. Hill, United States of America  
• Describe the recent resurgence and outbreaks of measles and the role of travel in its spread.  
• Review the implications of the changing epidemiology of measles for the traveller and for prevention.  
SY8.2 Worldwide Resurgence of Bordetella Pertussis – Addressing a Public Health Concern  
Mike Starr, Australia  
• Describe the recent resurgence and outbreaks of pertussis and efforts that have been made to control its spread.  
• Review the implications of the changing epidemiology of pertussis for the traveller and opportunities for prevention.  
SY8.3 Polio  
David L. Heymann, United Kingdom  
• Describe the past and present history of the polio eradication program and highlight the successes achieved and the challenges encountered.  
• Review the implications of global travel in the eradication efforts for polio. | Auditorium, Level 1 |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| **WS9** 14.45-16.15 | **Workshop 9**  
How to Prevent and Manage Acute and Chronic Diarrhoea in Travellers  
David R. Shlim, United States of America  
Darius Soonawala, The Netherlands  
- Recognize the clinical presentation of new causative agents of traveller’s diarrhoea.  
- Translate knowledge on increasing resistance to antimicrobial treatment of traveller’s diarrhoea into practice.  
- Critically appraise the need for stand-by treatment.  
- Discuss the diagnostic work-up of chronic diarrhoea. | **Paris, Level 0 Room 0.5** |
| **SY9** 14.45-16.15 | **Symposium 9**  
Virtual Tools in Travel Medicine  
*Chairs:* Peter A. Leggat, Australia  
Anne McCarthy, Canada  
**SY9.1 Social Media in the Practice of Travel Medicine**  
Deborah Mills, Australia  
- Available and possible platforms for interaction with the traveller including twitter, facebook, linkedin.  
- The learner will be able to instruct travellers on social modalities that are accessible during travel.  
**SY9.2 Development of In-Travel Surveillance Methods**  
Emily S. Jentes, United States of America  
- Review existing tools for monitoring travel morbidity while on a trip.  
- Discuss web-based, cell phone based and tablet based methodologies in development to monitor travellers for trip associated illness.  
**SY9.3 Support for Travellers Abroad by the Travel Clinic**  
Kerryann Cope, United Kingdom  
- Discuss and review pros and cons of e-mail, telephone, web-based support for acute and chronic medical problems while overseas.  
- Modalities for ongoing delivery of wellness messages for the traveller.  
- Online personal health spaces to support resilience during overseas travel and postings. | **Brussels, Level 0 Room 0.5** |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>FC5</td>
<td>Free Communication 5</td>
<td>Rome, Level 0</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td>Chronic Infections in Migrants</td>
<td>Room 0.8</td>
</tr>
<tr>
<td></td>
<td>Chairs: Masatoki Adachi, Japan, Rogelio López-Vélez, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td>FC5.1 Barriers to the Provision of Pre-Travel Preventative Health Advice in Primary Care to Australian Travellers Visiting Friends and Relatives</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bradley L. Forssman, Australia</td>
<td></td>
</tr>
<tr>
<td>15.00-15.15</td>
<td>FC5.2 Situational Analysis of HIV Travel Restrictions for Migrants</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Annelies Wilder-Smith, Singapore</td>
<td></td>
</tr>
<tr>
<td>15.15-15.30</td>
<td>FC5.3 Clinical and Epidemiological Profile of HIV Infection among Migrant vs Italian Patients in Seven Italian Centers between 2000 and 2011</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Giorgia Sulis, Italy</td>
<td></td>
</tr>
<tr>
<td>15.30-15.45</td>
<td>FC5.4 Prevalence of Chronic Hepatitis B Virus Infection in African Immigrants seen at a U.S. Urban Travel Health Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stefan Hagmann, United States of America</td>
<td></td>
</tr>
<tr>
<td>15.45-16.00</td>
<td>FC5.5 Hepatitis B and Migrants: Should We Do Better?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Manon Jaboyedoff, Switzerland</td>
<td></td>
</tr>
<tr>
<td>16.00-16.15</td>
<td>FC5.6 Screening for Chagas Disease in Switzerland: One Size Fits All?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Valérie D'Acremont, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>WS10</td>
<td><strong>Workshop 10</strong>&lt;br&gt;Safe Transport: Carrying Meds and Needles and Accessing Medications Abroad&lt;br&gt;Jeff Goad, United States of America&lt;br&gt;Larry Goodyer, United Kingdom&lt;br&gt;• Formulate recommendations how to keep drugs cool during travel.&lt;br&gt;• Outline rules and regulations on travelling with medication.&lt;br&gt;• Explain how to carry sharps safely with you.&lt;br&gt;• Discuss access of medication abroad.</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td>16.15-17.00</td>
<td><strong>Afternoon Break</strong>&lt;br&gt;<strong>Poster Tours</strong>&lt;br&gt;(Meet Tour Leaders at Entrance of Exhibition)&lt;br&gt;Migrants&lt;br&gt;Louis Loutan, Switzerland&lt;br&gt;Returning Travellers&lt;br&gt;Christina Greenaway, Canada&lt;br&gt;Vaccines&lt;br&gt;Ursula Wiedermann, Austria</td>
<td>Exhibition, Level 1</td>
</tr>
<tr>
<td>SY10</td>
<td><strong>Symposium 10</strong>&lt;br&gt;Who Is Giving Travel Advice? An International, Multi-Professional Perspective&lt;br&gt;Chairs: Lee Baker, South Africa&lt;br&gt;Fiona Genasi, United Kingdom&lt;br&gt;SY10.1 Physician Perspective&lt;br&gt;Gerard JB Sonder, The Netherlands&lt;br&gt;SY10.2 Nurse Perspective&lt;br&gt;Sheila C. K. Hall, United Kingdom&lt;br&gt;SY10.3 Pharmacist Perspective&lt;br&gt;Karl M. Hess, United States of America&lt;br&gt;• Review travel health care provision internationally from the perspective of 3 different professional groups.&lt;br&gt;• Debate the relative strengths, weaknesses, opportunities, and threats that these 3 groups face when providing travel health services.</td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>WS11</td>
<td><strong>Workshop 11</strong></td>
<td>Brussels, Level 0 Room 0.4</td>
</tr>
<tr>
<td>17.00-18.30</td>
<td>Preventing Malaria: Common Problems, Possible Solutions&lt;br&gt;Lin H. Chen, United States of America&lt;br&gt;Patricia Schlagenhauf, Switzerland&lt;br&gt;• 3-4 case studies will be discussed. Malaria prevention in infants (repellents and chemoprophylaxis), in long-term residents (+LLIN), and pregnant women will be discussed.</td>
<td></td>
</tr>
<tr>
<td>FC6</td>
<td><strong>Free Communication 6</strong></td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>17.00-18.30</td>
<td>Immunizations: Safety, Immunogenicity and Availability&lt;br&gt;Chairs: Anthony Gherardin, Australia&lt;br&gt;Elaine Rosenblatt, United States of America</td>
<td></td>
</tr>
<tr>
<td>17.00-17.15</td>
<td><strong>FC6.1 Safety and Efficacy of a Patch Containing Heat-labile Toxin from Enterotoxigenic Escherichia coli (ETEC) Against Diarrhoea in Traveler’s to Mexico / Guatemala: A Randomized, Double-blind, Placebo-Controlled Phase 3 Trial</strong>&lt;br&gt;Ron H. Behrens, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>17.15-17.30</td>
<td><strong>FC6.2 Tick-borne Encephalitis: Long-term Follow-up and Effect of Immunity against Japanese Encephalitis and Yellow Fever</strong>&lt;br&gt;Herwig Kollaritsch, Austria</td>
<td></td>
</tr>
<tr>
<td>17.30-17.45</td>
<td><strong>FC6.3 Immunity after Yellow Fever Vaccination in Travellers Using Immunosuppressive Medication</strong>&lt;br&gt;Rosanne W. Wieten, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>17.45-18.00</td>
<td><strong>FC6.4 Seroconversion after Fendrix Hepatitis B Vaccination in 60 Non-responders</strong>&lt;br&gt;Rosanne W. Wieten, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
</tbody>
</table>
| 18.00-18.15 | **FC6.5** *Initial Neutralising Antibody Response on Day 35 after Two Different Intradermal Rabies Pre-exposure Vaccination Schedules: Preliminary Unpooled Data of a Large Prospective Clinical Trial on Rabies Boostability*  
*Patrick Soentjen, Belgium* | Rome, Level 0 Room 0.8 |
*Emily S. Jentes, United States of America* | Rome, Level 0 Room 0.8 |
| 17.00-18.30 | **Debate**  
*Clots or Shots: Heparin for Travellers, Pro and Con*  
*Pro: Susan Kahn, Canada  
Con: Benjamin Brenner, Israel  
Moderator: Alan J. Magill, United States of America*  
*Review the epidemiology and risk factors for clotting during travel and different therapeutic options for prevention.  
Present the pros and cons of providing heparin pre-travel to prevent thrombosis and embolism.* | Rome, Level 0 Room 0.8 |
|            | **WS12**  
**Workshop 12**  
*Safe Shots: Practical Aspects of Vaccine Administration (ABC)*  
*Julie Richards, United States of America  
Hilary Simons, United Kingdom*  
*Review basic information about vaccine storage, handling and administration, including length of needles; simultaneous injections; administration to special populations (e.g., post mastectomy; anticoagulated); avoiding syncope after injections.* | Athens, Level 0 Room 0.9 |
<p>| 18.30-19.15 | <strong>ISTM Migrant and Refugee Special Interest Group General Assembly</strong> | Paris, Level 0 Room 0.5 |
| 18.30-19.15 | <strong>ISTM Nursing Professional Group General Assembly</strong> | Rome, Level 0 Room 0.8 |
| 18.30-19.15 | <strong>ISTM Pharmacist Professional Group General Assembly</strong> | Athens, Level 0 Room 0.9 |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTH3</td>
<td>Meet the History 3</td>
<td>Paris, Level 0, Room 0.5</td>
</tr>
</tbody>
</table>
| 08.00-08.45 | History of Verenigde Oostindische Compagnie (VOC)  
or The Dutch East India Company  
Otto Bleker, The Netherlands |                                  |
|          | • The VOC or Dutch East India Company, established in 1602 by the States General of Holland, had a monopoly to carry out commercial, political and military activities in Asia. Between 1602 and 1796 it sent almost a million Europeans on 4785 ships and netted more than 2.5 million tons of Asian trade goods.  
• The medical service of the VOC will be discussed; especially the ship's surgeons in the eighteenth century. |                                  |
<p>| COD3     | Case of the Day 3                            | Rome, Level 0, Room 0.8          |
| 08.00-08.45 | Philip R. Fischer, United States of America |                                  |
| MTP3     | Meet the Professor                           | Athens, Level 0, Room 0.9        |
| 08.00-08.45 | Session Cancelled                           |                                  |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| PL3 09.00-10.30 | **Plenary 3**  
*One Health: Travellers and Zoonoses*
*Chairs: David O. Freedman, United States of America  
Christina Greenaway, Canada*  
PL3.1 *Zoonoses in a Global World*
*Roel Coutinho, The Netherlands*  
- Describe how emerging infections are linked to increasing contact between humans and wildlife.
- Describe how global trade/travel exacerbates the problem of zoonotic disease emergence: SARS etc.  
PL3.2 *One Health: Clinical Implications for Travel Medicine*
*Peter M. Rabinowitz, United States of America*  
- Review the origin and objectives of the One Health Initiative.
- Review how the animals and the environment that human contact can affect their health and vice versa.
- Discuss the human health risks related to contact with animals while traveling including: Direct contact with wildlife and wildlife souvenirs; Direct contact with companion animals; and Contact with high risk environments.
- Learn how illnesses in animals can be a sentinel for disease in humans.  
PL3.3 *Travelling Humans and Travelling Animals: Health Risks from an Animal Perspective*
*Corrie C. Brown, United States of America*  
- Review the connections between human, animal and environmental health with a focus on diseases from an animal perspective: reverse zoonoses due to ecotourism.
- Describe pre-travel and post-travel evaluation of pets.
- Review diseases that travelling pets can import home and spread to the human community.  
<p>| 10.30-11.15 | Morning Break                                                           | Exhibition Level 1              |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LBSY</strong></td>
<td><strong>Late Breaker Symposium</strong>&lt;br&gt;Changing Viral Infections in Europe and Africa (Emerging Viral Pathogens)&lt;br&gt;&lt;em&gt;Chairs:&lt;/em&gt; Garth Brink, South Africa&lt;br&gt;Thomas Löscher, Germany</td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td><strong>11.15-12.45</strong></td>
<td><strong>LB1.1 Novel Respiratory Pathogens</strong>&lt;br&gt;Ron Fouchier, The Netherlands&lt;br&gt;<strong>LB1.2 Medically Important Arboviruses in Europe</strong>&lt;br&gt;Natalie Cleton, The Netherlands&lt;br&gt;<strong>LB1.3 Haemorrhagic Fever in Africa</strong>&lt;br&gt;Daniel Bausch, United States of America</td>
<td></td>
</tr>
<tr>
<td><strong>SY11</strong></td>
<td><strong>Symposium 11</strong>&lt;br&gt;Expatriate Health Issues: Preparation and Living Abroad&lt;br&gt;&lt;em&gt;Chairs:&lt;/em&gt; Prativa Pandey, Nepal&lt;br&gt;Frank von Sonnenburg, Germany</td>
<td>Brussels, Level 0 Room 0.4</td>
</tr>
<tr>
<td><strong>11.15-12.45</strong></td>
<td><strong>SY11.1 Mental Health in Expats</strong>&lt;br&gt;Sarah Borwein, Hong Kong&lt;br&gt;• Review epidemiology of mental health problems in expats.&lt;br&gt;• Review interventions that can be applied before or during travel to try to minimize mental health problems.&lt;br&gt;<strong>SY11.2 Health Problems and Preparing</strong>&lt;br&gt;Poh Lian Lim, Singapore&lt;br&gt;• Review health problems that are most common in expats and how they vary by type of expat.&lt;br&gt;• Review interventions that are effective.&lt;br&gt;<strong>SY11.3 Family Cycle Abroad</strong>&lt;br&gt;Michael E. Jones, United Kingdom&lt;br&gt;• Review practical challenges of dealing with health, social, educational, political, emergency, and other issues while living abroad.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>WS13</td>
<td><strong>Workshop 13</strong>&lt;br&gt;Sex Tourism: What Travel Medicine Practitioners Need to Know&lt;br&gt;<strong>Irmgard Bauer</strong>, Australia&lt;br&gt;<strong>Alberto Matteelli</strong>, Italy&lt;br&gt;• Describe the range of activities that fall within the definition of sexual tourism.&lt;br&gt;• Describe origin of and trends in sexual tourism and regional variations.</td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>WS14</td>
<td><strong>Workshop 14</strong>&lt;br&gt;Brazil and High Altitude Destinations in South America (Destination)&lt;br&gt;<strong>Jesse Alves</strong>, Brazil&lt;br&gt;<strong>Cecilia Perret</strong>, Chile&lt;br&gt;• Describe characteristics and risks of common destinations in Brazil and Latin America, including high altitude destinations.&lt;br&gt;• Describe characteristics of locations for the World Cup and Summer Olympics.</td>
<td>Rome, Level 0 Room 0.8</td>
</tr>
<tr>
<td>FC7</td>
<td><strong>Free Communication 7</strong>&lt;br&gt;Airlines, Altitude and Study Methods&lt;br&gt;<strong>Chairs</strong>: <strong>Yves Van Laethem</strong>, Belgium&lt;br&gt;<strong>Christopher Van Tilburg</strong>, United States of America</td>
<td>Athens, Level 0 Room 0.9</td>
</tr>
<tr>
<td>11.15-11.30</td>
<td><strong>FC7.1 In-flight Medical Incidents, Deaths and Flight Diversions of South African Airways Flights from 2009 till 2011</strong>&lt;br&gt;<strong>Salim Parker</strong>, South Africa</td>
<td></td>
</tr>
<tr>
<td>11.30-11.45</td>
<td><strong>FC7.2 Incidence of Serious Altitude Sickness in Travellers who Consulted a Pre-travel Clinic</strong>&lt;br&gt;<strong>Mieke Croughs</strong>, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>11.45-12.00</td>
<td><strong>FC7.3 The Diagnosis of Juvenile Acute Mountain Sickness (AMS)</strong>&lt;br&gt;<strong>Tadashi Shinozuka</strong>, Japan</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
</tbody>
</table>
| 12.00-12.15  | **FC7.4** The Role of Travellers from South East Asia on Dengue Activity in Singapore  
Eduardo Massad, Brazil                              |                               |
| 12.15-12.30  | **FC7.5** Analyzing GeoSentinel Surveillance Data: A Comparison of Methods to Explore Acute Gastrointestinal Illness among International Travellers  
Katherine E. Mues, United States of America         |                               |
| 12.30-12.45  | **FC7.6** Pilot Randomised Controlled Trial to Testing Facemasks Effectiveness in Preventing Influenza-like Illness Transmission among Hajj Pilgrims  
Ohsamah Barasheed, Australia                        |                               |
<p>| 12.45-14.45  | Lunch Break                                                              | Exhibition, Level 1            |
| 13.15-14.30  | <strong>ISTM GeoSentinel/EuroTravNet/CanTravNet Network Member Meeting</strong>        | Rome, Level 0 Room 0.8        |
|              | • Open to all                                                            |                               |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY12</td>
<td><strong>Symposium 12</strong></td>
<td>Auditorium,</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>What Is the Diagnosis? Tests in Travellers</strong></td>
<td>Level 1</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Martin Haditsch, Austria and Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mary-Louise Scully, United States of America</td>
<td></td>
</tr>
<tr>
<td>SY12.1</td>
<td><strong>Use of IGRA in Travellers and Immigrants</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Kevin Schwartzman, Canada</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the principles and limitations of interferon-gamma release</td>
<td></td>
</tr>
<tr>
<td></td>
<td>assays for the diagnosis of (latent) tuberculosis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Interpret the findings of Mantoux testing and IGRA in returning</td>
<td></td>
</tr>
<tr>
<td></td>
<td>travellers and immigrants.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Determine when to use Mantoux testing or IGRA in returning travellers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and immigrants for screening of latent TB.</td>
<td></td>
</tr>
<tr>
<td>SY12.2</td>
<td><strong>Usefulness of Molecular Diagnosis in PCR Stools</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Lisette van Lieshout, The Netherlands</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discussion on the limitations of microscopy for diagnosis of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>parasitic diseases has a limited sensitivity (microsporidium,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>strongyloides), specificity (E. histolytica vs E. dispar).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Presentation of study results demonstrating the usefulness of PCR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>for diagnosis of parasitic diseases.</td>
<td></td>
</tr>
<tr>
<td>SY12.3</td>
<td><strong>Pitfalls and Practice with Rapid Diagnostic Tests</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Emmanuel Bottieau, Belgium</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Short introduction about diagnostic tests and sensitivity,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>specificity and likelihood ratio’s.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Presentation of study results demonstrating usefulness of RDT for</td>
<td></td>
</tr>
<tr>
<td></td>
<td>malaria, dengue fever, leptospirosis, others.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>LBS</td>
<td><strong>Late Breaker Special Session</strong></td>
<td>Brussels, Level 0 Room 0.4</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>Updates on JE Vaccines and Ongoing Outbreak of Sarcocystosis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs:</em> David Hamer, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gerard JB Sonder, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LBS1.1 Japanese Encephalitis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marc Fischer, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LBS1.2 Japanese Encephalitis Vaccine</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Katrin Dubischar-Kastner, Austria</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LBS1.3 Sarcocystosis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Douglas Esposito, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LBS1.4 A Family Cluster of Sarcocystosis in Travelers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>returning from Tioman Island, Malaysia, including a Histologically Proven Case with Results of Treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Loïc Epelboin, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>LBS1.5 Cluster of Acute Muscular Sarcocystis-like Infection in 12 Travelers Returning from Peninsular Malaysia, 2012, Bordeaux, France</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Duc Nguyen, France</td>
<td></td>
</tr>
<tr>
<td>WS15</td>
<td><strong>Workshop 15</strong></td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>Pox, Pustules and Lumps: Skin Lesions in Returned Travellers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eric Caumes, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jay Keystone, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• In a case based format review the most common skin lesions acquired during travel and provide a practical approach to diagnosis and management.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
</tbody>
</table>
| WS16       | Workshop 16  
14.45-16.15  
On the Road with HIV  
Francesco Castelli, Italy  
Marc Mendelson, South Africa  
• 3-4 case studies will be discussed. Susceptibility for specific infections will be debated. Examples of possible interactions between antimalarials and antiretroviral therapies will be given. Useful websites addresses to predict drug-drug interactions will be provided. | Rome, Level 0  
Room 0.8 |
| WS17       | Workshop 17  
14.45-16.15  
Babes on the Road: Pregnant and Infant Travellers  
I. Dale Carroll, United States of America  
Catherine Riley, United Kingdom  
• In a case based format review a practical approach to providing pre-travel advice for commonly encountered issues of prevention, prophylaxis and treatment specific to pregnant and infant travellers. | Athens, Level 0  
Room 0.9 |
| 16.15-17.15| Afternoon Break and Poster Session                                  | Exhibition,  
Level 1                           |
| 17.15-18.45| ISTM Membership Assembly                                            | Auditorium,  
Level 1                           |
| 18.45-19.30| Cocktail Reception for ISTM Members                                   | Auditorium,  
Level 1                           |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>COD4</td>
<td>Case of the Day 4</td>
<td>Paris, Level 0 Room 0.5</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Philippe Parola, France</td>
<td></td>
</tr>
<tr>
<td>SY13</td>
<td>Symposium 13</td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td>Fit for Travel: Trip Prep for Older Travellers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Eric Caumes, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mary-Louise Scully, United States of America</td>
<td></td>
</tr>
<tr>
<td>SY13.1</td>
<td>Polypharmacy and Travel Medicines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Caroline Zeind, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review of changed pharmacokinetics and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>pharmacodynamics of frequently used drugs in elderly.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Judge frequently used drugs in elderly on</td>
<td></td>
</tr>
<tr>
<td></td>
<td>possible side effects due to anticholinergic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>activity.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how to prevent potential severe adverse</td>
<td></td>
</tr>
<tr>
<td></td>
<td>events of diuretics, NSAID, ACE-inhibitors and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>statins during dehydration.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Apply tools to tackle polypharmacy in elderly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>travelers.</td>
<td></td>
</tr>
<tr>
<td>SY13.2</td>
<td>Evaluation of Fitness for Travel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jan Hindrik Ravesloot, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Give examples of age-related physiological</td>
<td></td>
</tr>
<tr>
<td></td>
<td>changes and explain their clinical significance.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Name tests for physical activity, fitness and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>longevity in elderly.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Assess fitness for travel in elderly traveller.</td>
<td></td>
</tr>
<tr>
<td>SY13.3</td>
<td>Immunosenescence and Vaccines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brian Ward, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List changes in innate and adaptive immunity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>during old age.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Give examples of increased infectious risks due</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to immunosenescence.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss consequences of immunosenescence for</td>
<td></td>
</tr>
<tr>
<td></td>
<td>secondary immune response to travel vaccines.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss consequences of immunosenescence for</td>
<td></td>
</tr>
<tr>
<td></td>
<td>primary immune response to travel vaccines.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>WS18</td>
<td><strong>Workshop 18</strong></td>
<td>Brussels, Level 0</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><em>Leish Basics: Diagnosis and Treatment of Leishmaniasis</em></td>
<td>Room 0.4</td>
</tr>
<tr>
<td></td>
<td>Johannes Blum, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Andrea K. Boggild, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 3 case studies discussed will provide a review of diagnostic tests</td>
<td></td>
</tr>
<tr>
<td></td>
<td>available and their indication as well as a review of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>treatments available for the most frequent Leish species.</td>
<td></td>
</tr>
<tr>
<td>WS19</td>
<td><strong>Workshop 19</strong></td>
<td>Paris, Level 0</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>The Humanitarian Aid Worker: Ethics and Preparation</strong></td>
<td>Room 0.5</td>
</tr>
<tr>
<td></td>
<td>Ted Lankester, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Christopher Van Tilburg, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review specific risks and situations related to the provision of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>humanitarian care.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain how to prepare for these specific risk and situations such</td>
<td></td>
</tr>
<tr>
<td></td>
<td>as: exposure to the specific environment, such as in a natural</td>
<td></td>
</tr>
<tr>
<td></td>
<td>disaster or conflict; working long hours under adverse or extreme</td>
<td></td>
</tr>
<tr>
<td></td>
<td>conditions; damaged or absent infrastructure; reduced levels of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>security.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss how to appraise stress, ethical, and moral challenges</td>
<td></td>
</tr>
<tr>
<td></td>
<td>related to the event and the resource capacities of the situation.</td>
<td></td>
</tr>
<tr>
<td>10.30-10.45</td>
<td><strong>Morning Break</strong></td>
<td>Auditorium Foyer,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Level 1</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>10.45-12.15</td>
<td><strong>Plenary 4</strong></td>
<td>Auditorium, Level 1</td>
</tr>
<tr>
<td></td>
<td><strong>Mass Gatherings: Local and Global Consequences</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Fiona Genasi, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>David R. Shlim, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL4.1 Non-communicable Health Risks During Mass Gatherings</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Robert Steffen,</strong> Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the leading causes of mortality and morbidity during mass</td>
<td></td>
</tr>
<tr>
<td></td>
<td>gatherings; human stampedes and heat-related illnesses are the leading</td>
<td></td>
</tr>
<tr>
<td></td>
<td>causes of mortality; warm weather, extreme weather conditions and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>emotional stress of morbidity.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize traveller’s characteristics associated with increased risk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of illness or injury.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Women, very young and very old are more vulnerable during mass</td>
<td></td>
</tr>
<tr>
<td></td>
<td>gatherings.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Formulate health advice to reduce illness and injury; effective</td>
<td></td>
</tr>
<tr>
<td></td>
<td>strategies to prevent heat stroke, cardiovascular accidents.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL4.2 Maha Kumbh Mela, Largest Public Gathering in the World</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Satchit Balsari,</strong> United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the public health risks and how these health risks were met.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review implications for global health security.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• New aspects of surveillance that have been put in place for 2012 and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>as part of our legacy will be covered.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>**PL4.3 Lessons Learned from the 2012 Summer Olympics: London's</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Preparations for the Global Visitor**</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Brian McCloskey,</strong> United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lessons learned for the global traveller: exchange of experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>between organisers and hosts of mass gathering provide the opportunity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to formulate guidelines generally applicable in all countries of the</td>
<td></td>
</tr>
<tr>
<td></td>
<td>world.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discussion on the international collaboration with WHO and ECDC and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>the role of the WHO Collaborating Centre here.</td>
<td></td>
</tr>
<tr>
<td>12.15-12.45</td>
<td><strong>Closing Ceremony</strong></td>
<td>Auditorium, Level 1</td>
</tr>
</tbody>
</table>
The International Society of Travel Medicine Certificate of Knowledge is a symbol of achievement in the field of travel medicine. As the first international certificate devoted solely to travel health, it recognizes professionals who have demonstrated expertise in the unique body of knowledge associated with the practice of travel medicine.

**Wednesday, 7 May 2014**
in **Ho Chi Minh City, Vietnam**

*In conjunction with the*

10th Asia Pacific Travel Health Conference

---

**Sunday, 3 August 2014**
in **Jackson Hole, Wyoming USA**

*in conjunction with the*

6th Regional Conference of the International Society of Travel Medicine

*and the*

2014 Summer Conference of the Wilderness Medical Society

To register for the Exam, or for more information, go to www.ISTM.org.
Posters

Airline or Maritime Medicine

PO01.01
Retrospective Study of Deaths of Air Travelers Attended at Chhatrapati Shivaji International Airport, Mumbai
A.D. More
Mumbai International Airport Pvt Ltd, Medical Services, Mumbai, India

PO01.02
Medical Problems Encountered during Two Circumnavigations by Semester at Sea
P.D. Sloane, A. Herweck, A. Mailey, S. Zimmerman
University of North Carolina - Chapel Hill, Family Medicine, Chapel Hill, United States, University of San Diego, San Diego, United States, University of North Carolina - Chapel Hill, Cecil G Sheps Center for Health Services Research, Chapel Hill, United States

PO01.03
Plasmodium ovale in Seafarers on Greek Merchant Ships Calling at African Ports
E. Vassalou, C.M. Vassalos, G. Spanakos, N. Vakalis
National School of Public Health, Department of Parasitology and Tropical Diseases, Athens, Greece

Altitude, Diving or Environmental Exposures

PO02.01
Vibrio and Stenotrophomonas in the Caribbean Sea: A Potential Source of Infections in Divers and Snorkelers
R. Naraine, K. Farmer, S. Kotelnikova
St. George's University, Microbiology, St. George, Grenada

PO02.02
Drug Resistance and Frequencies of Resistant E.coli and E.fecalis in Oceanic Tropical Waters of Grenada
S. Kotelnikova, V. Amadi
St. George's University, Microbiology, St. George's, Grenada

PO02.03
Potentially Dangerous Consequences of a Bad-Managed Pre-travel Consultation
A. Rossanese, F. Gobbi
'Sacro Cuore-Don Calabria' Hospital, Centre for Tropical Diseases, Negrar, Verona, Italy

PO02.04
Acute Mountain Sickness Complicated by High-Altitude Pulmonary Edema and High-Altitude Cerebral Edema in a 35-Year Old Hong Kong Traveler Visiting Lake Titicaca, Peru
C.K.B. Wong
Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

Enteric Infections

PO03.01
Strongyloides Stercoralis as a Cause of Enteric Infection Is Underestimated in Slovenia and in Balkan Region
M. Skvarc, P. Rogina
Faculty of Medicine Ljubljana, Institute of Microbiology and Immunology, Ljubljana, Slovenia, General Hospital Novo Mesto, Novo Mesto, Slovenia

PO03.02
Safety and Efficacy of a Travelers' Diarrhea Patch Vaccine System Containing Heat-labile Toxin from Enterotoxigenic Escherichia coli (ETEC) in Travelers to Asia: A Randomized, Double-blind, Placebo-Controlled Phase 2 Trial
University Medical Center Hamburg-Eppendorf (UKE), Department of Tropical Medicine, Hamburg, Germany, Bernhard Nocht Institute for Tropical Medicine, Clinical Research Department, Hamburg, Germany, Hospital for Tropical Diseases, Travel Medicine, London, United Kingdom, Berliner Centrum Reise & Tropenmedizin, Berlin, Germany, Prabhugaunker's Clinic, Goa, India, Wellesley Medicentre, Kolkata, India, Intercell AG., Vienna, Austria, University of Zurich, Institute of Social and Preventive Medicine, Division of Epidemiology and Prevention of Communicable Diseases, Zurich, Switzerland
PO03.03
Characterization of Enterotoxigenic Escherichia Coli Strains in Patients with Acute Diarrhea in Mexico, Guatemala, India and United States
Z.-D. Jiang1, V. Kharat1, J.A. Boom2, L.C. Sahni2, H.L. Dupont1
1University of Texas, Houston, United States, 2Texas Children’s Hospital, Houston, United States

PO03.04
Rapid Cessation of Acute Diarrhea in Pediatric Patients Using a Novel Plant Extract: Results of a Randomized, Cross-over Study
A.S. Dover1
1LiveLeaf Bioscience, Inc., San Carlos, United States

PO03.05
Traveler’s Diarrhea among Foreign Travelers in Southeast Asia
C. Kittitrakul1, W. Priyaphanee1, W. Tangkanakul2, S. Lawpoolsiri3
1Mahidol University, Department of Clinical Tropical Medicine, Bangkok, Thailand, 2Ministry of Public Health, Department of Disease Control, Bangkok, Thailand, 3Mahidol University, Department of Tropical Hygiene, Bangkok, Thailand

PO03.06
Intestinal Parasitism in Business Travellers from 2002 to 2012: Review of 17536 Fecal Specimens
Analysis in a French Travel Clinic Laboratory
M. Plisson-Sauné1, X. Chanudet1, D. Martin1, I. Tawa1, P. Piot1, N. Poullbère1, M. Carsault1, F. Tournois1, O. Marensowski1, L. Perhuso1
1CMETE, Paris, France

PO03.07
The Importance of Norovirus as a Cause of Travelers’ Diarrhea Is Ill Defined and Underestimated
T. Verstraeten1
1P95, Pharmacovigilance and Epidemiology Services, Leuven, Belgium

PO03.08
Case Report of an Outbreak of norovirus on a Cruise Ship
H. Visser1
1Public Health Service Rotterdam-Rijnmond, Infectious Disease Control, Rotterdam, Netherlands

PO03.09
A Description of Enteric Fever Cases in Auckland, New Zealand from 2005 to 2010
R.J. Land1, S. Mc Bride2, D. Holland1, S. Perera3, T. Jelleyman3, K. Read1, R.J.H. Ingram3
1Middlemore Hospital, Infectious Diseases, Auckland, New Zealand, 2Auckland Regional Public Health Service, Auckland, New Zealand, 3Waitakere Hospital, Auckland, New Zealand, 4North Shore Hospital, Auckland, New Zealand, 5Auckland City Hospital, Infectious Diseases, Auckland, New Zealand

PO03.10
Amebic Liver Abscess: Epidemiological, Clinical Data and Outcome in a Series of 53 Travelers
C. Rapp1, C. Valentin1, C. Verret1, J. Mergery1, F. Simon1, T. Carmol2, C. Ficko2, O. Aoun1
1Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, 2Begin Military Hospital, Saint-Mandé, France, 3CESPA, Paris, France, 4HIA Percy, Clamart, France, 5HIA Laveran, Marseille, France, 6HIA Val de Grace, Paris, France

Infectious Diseases: Epidemiology, Diagnosis, Treatment

PO04.01
Case report: Acute Miliary Tuberculosis Aeromedical Evacuation with a Positive Pressure Aircraft Transit Isolator
H. Raffin1,2
1Medi’Air International, Bagneot, France, 2SAMU de Paris, DAR Neckar Enfants-Malades, Paris, France

PO04.02
Reasons for Outpatient Visits by Foreign Travellers to an Urban Hospital in Tokyo
N. Matsuda1, T. Naito1, Y. Uehara1, H. Isonuma1, T. Hisaoka1
1Juntendo University, General Medicine, Bunkyo-ku, Japan
Abstracts - Poster Presentations

PO04.03
Prevalence of Placental Toxoplasmosis in the Greater Accra Region of Ghana
Noguchi Memorial Institute for Medical Research, Parasitology Department, Accra, Ghana, Kwame Nkrumah University of Science and Technology, Clinical Microbiology, SMS, Kumasi, Ghana, Korle-Bu Teaching Hospital, Obstetrics and Gynaecology Department, Korle-Bu, Accra, Ghana, Tokyo Medical and Dental University, Department of Environmental Parasitology, Tokyo, Japan

PO04.04
Possible and Proven Mixed Infection of Schistosomiasis and Strongyloidosis: A Single Centre Retrospective Analysis
P. Soentjens, A. Aerssens, J. Verschueren, D. Van den Bossche, M. Van Esbroeck
Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium, Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, Military Hospital Queen Astrid, Lab Department, Brussels, Belgium

PO04.05
Schistosomiasis Serology in Travellers and Immigrants Returning to Edinburgh, UK: A Retrospective Preliminary Analysis
S. Durkin, C. Alexander, K.O. Helgason, M.E. Jones
Edinburgh University, Edinburgh, United Kingdom, Stobhill Hospital, Scottish Parasitology Laboratory, Glasgow, United Kingdom, Royal Infirmary of Edinburgh, Microbiology, Edinburgh, United Kingdom, Western General Hospital, Regional Infectious Diseases Unit, Edinburgh, United Kingdom

PO04.06
Mapping of Filaria Infection in Domestic Cats Living in Brugian Filariasis-endemic Areas Using a Real Time PCR with HRM Analysis
S. Wongkamchai, H. Nochot, S. Foongladda, P. Dekumyoy, S. Loymek, J.J.J. Boitaino, W. Choochote
Mahidol University, Parasitology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, Mahidol University, Microbiology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, Mahidol University, Helminthology, Faculty of Tropical Medicine, Bangkok, Thailand, Filaria Project, Phikulthong Royal Development Study Center, Narathiwat, Thailand, Chiangmai University, Parasitology Faculty of Medicine, Chiangmai, Thailand

PO04.07
Candida Species of Bloodstream Isolates and Antifungal Susceptibility of Candida in the Biggest Tertiary Hospital in Thailand
S. Foongladda, P. Petlum, D. Boonlert, N. Mongkol
Mahidol University, Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand

PO04.08
Evaluation of the Diagnosis of Travel-related Acute Schistosomiasis Syndrome by Serum PCR: Expertise from a Single Centre
L. Cnops, P. Soentjens, J. Clerinx, M. Van Esbroeck
Institute of Tropical Medicine, Antwerp, Belgium, Military Hospital Queen Astrid, Brussel, Belgium

PO04.09
What Infectious Diseases Are Mostly Reported Following Travelling Abroad? What Types of Travelers Are Affected? Norway, 2011
B. Guzman Herrador, T. Bruun, L. Vold, H. Blystad
Norwegian Institute of Public Health, Oslo, Norway

PO04.10
Imported Human Rabies Cases Worldwide, 1990-2012
P. Carrara, P. Parola, P. Broqui, P. Gautret
IHU Méditerranée Infection, Marseille, France

PO04.11
Recombinant Nonstructural 1 (NS1) Protein of Dengue Virus for Diagnosis of Dengue Virus Infection
U. Kositanont, P. Panyarakkit, S. Anantaprecha
Faculty of Medicine Siriraj Hospital, Mahidol University, Department of Microbiology, Bangkok, Thailand, National Institute of Health, Ministry of Public Health, Department of Medical Sciences, Nonthaburi, Thailand

PO04.12
Severe Malaria in Canada: Management through the Canadian Malaria Network
A.E. McCarthy, J. Geduld, C. Prematunga, on behalf of the Canada Malaria Network
University of Ottawa and the Ottawa Hospital, Dept of Medicine, Ottawa, Canada, Public Health Agency of Canada, Ottawa, Canada, University of Ottawa, Ottawa, Canada
PO04.13 One Case of Cerebral Falciparum Malaria Onset as Thrombocytopenia in a Returning Traveller from China
X.-Y. Wang1, S.-L. Yu1, Y.-X. Huang1, W.-H. Zhang1
1Huashan Hospital, Fudan University, Department of Infectious Diseases, Shanghai, China

Long-stay Travellers, including expatriates

PO05.01 A Travel Clinic as a Company Hospital
K. Miyagi1, M. Nonaka1, M. Osabe1
1Nagasaki Shipyard & Machinery Works Hospital, Mitsubishi Heavy Industries, Ltd., Department of Internal Medicine, Nagasaki, Japan

PO05.02 The Medical Evacuation Response Plan (MERP) - a Tool for Companies to Perform Duty of Care for their Travelers and Expatriates While Working Abroad
S. Esser1
1International SOS, Central Europe Medical Department, Neu-Isenburg, Germany

PO05.03 High Proportion of Unprotected Casual Sexual Contacts among Dutch Long-Term Travellers to Sub-Tropical Countries, Though No Seroconversions for HIV or Syphilis
J. Whelan1,2, S. Belderok1,2, G. Sonde1,2, A. van den Hoek1,2
1Public Health Service (GGD), Department of Infectious Diseases, Amsterdam, Netherlands, 2Academic Medical Center/University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands

PO05.04 Changes in Expatriate Psychosocial Well-being during Overseas Assignment
K.L. Gamble1, D. Westwood2, J. Gamble2, N. Gamble2
1Missionary Health Institute, Canada, Canada, 2Missionary Health Institute, Toronto, Canada

Migrants and Refugees

PO06.01 Developing a Tool to Help Newcomers Refugees
S. Gagnon1, M. Chamula2, I. Pirja2
1CSSS de la Vieille-Capitale, Clinique Santé des Immigrants-Réfugiés, Québec, Canada, 2Université Laval, Etudiante, Québec, Canada

PO06.02 Health of Migrant and Travel Medicine: A New Approach for Visiting Friends and Relatives
L. Pecoraro1, T. D’Arca1, I. Uccella1, R. Testa1, G. Costanzo1, C. Mirisola1
1National Institute for Health, Migration and Poverty, Rome, Italy

PO06.03 Overseas Tuberculosis (TB) Screening in Peruvian Immigrants to United States
H.R. Siu1,2, N. Lari1, J. Echevarria1,2
1British American Hospital / Clínica Anglo Americana, Travel Medicine, Lima, Peru, 2Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru

PO06.04 Perception of Emotional and Behavioral Problems among Refugee Children Living in Canada
S. Gagnon1, M.-C. Duquette2, C. Rousseau3, P.G. Tremblay5
1Institut National de Santé Publique Du Québec, Québec, Canada, 2Centre Hospitalier Universitaire de Québec, Québec, Canada, 3Sick Children Hospital, Psychiatry, Montreal, Canada

PO06.05 Cases of Community-acquired MRSA (CA-MRSA) among Immigrants Seen in NYC Community Health Centers
N. Piper Jenks1, J.N. Tobin1,2, R.G. Kost1, S. Balachandra2, O. Okpukpara1, C. Khalda1, A. Tsang1, B. Rumala2, C. Colfran1, M. Pastaga2, T. Evering2, P. Holt1, H. de Lancastre2, A. Tomasz3, P. Pardos4, B. Collier2
1Clinical Directors Network (CDN) c/o HudsonRiver Community Health, Internal Medicine, Peekskill, United States, 2The Rockefeller University for Clinical and Translational Science (CCTS), New York, United States
PO06.06 Cases of Shingles (Herpes Zoster) among Young Healthy Migrants, during a Period of Increasing Varicella Vaccine Coverage
N. Piper Jenks1, J. Koren1, C. Kananen1, J. Yao1
1Hudson River Community Health, Internal Medicine, Peekskill, United States

PO06.07 Taeniasis among Refugees on the Thailand-Burma Border
E.J. McCleery1, P. Patchanee2, S. Chailangkam2, P. Pongsopawijit2, S. Tiwananthagorn2, P. Jongchansittos3, A. Dantrakool3, N. Morakote4, H. Phyu5, S. O'Neal1
1Oregon Health & Science University, Public Health & Preventive Medicine, Portland, United States, 2Chiang Mai University, Faculty of Veterinary Medicine, Chiang Mai, Thailand, 3Division of Livestock Development, Mae Hong Son, Thailand, 4Chiang Mai University, Faculty of Medicine, Department of Parasitology, Chiang Mai, Thailand, 5International Rescue Committee, Mae Hong Son, Thailand

PO06.08 Dramatrical Fall in Comoros-acquired Malaria in Marseille, France, 2001-2011
H. Savin1, C. Martel1, A. Ali Mohamed1, P. Gautret1, P. Minodier2, R. Pierroux2, P. Parola4, F. Simon1
1Military Teaching Hospital of Laveran, Unit of Infectious and Tropical Diseases, Marseille, France, 2Hôpital Nord, Assistance-Publique Hôpitaux de Marseille, Pediatric Emergency, Marseille, France, 3Assistance-Publique Hôpitaux de Marseille, Department of Parasitology and Mycology, Marseille, France, 4EuroTravNet Coordinating Center, University Hospital Institute for Infectious and Tropical Diseases, Aix-Marseille University and Assistance-Publique Hôpitaux de Marseille, Marseille, France

PO06.09 Description of Discrete Typing Units of Trypanosoma cruzi in Migrant Bolivian Patients with Chagas Disease: The Strains Remain the Same
J.A. Perez-Molina1, C. Poveda1, A. Martinez-Perez1, F. Guhl2, F. Norman1, M. Fresno3, R. Lopez-Velez1, N. Gironés2
1Hospital Ramon y Cajal, Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Madrid, Spain, 2Universidad de los Andes, Centro de Investigaciones en Microbiología y Parasitología Tropical, CIMPAT, Bogotá, Colombia, 3CSIC-UAM, Centro de Biología Molecular Severo Ochoa, Madrid, Spain

Non-infectious Disease Travel Risks (e.g., pulmonary emboli, jet lag)

PO07.01 Resurgence of Bed Bugs in Thailand and Their Insecticide Resistance: A Pest Control Challenge
A. Tawatsin1, U. Thavara1, J. Chompoosri1, P. Bhakdeenuan1, Y. Phusup1, S. Sangkitporn1, P. Siriyasatien2
1National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand, 2Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Occupational and Military Medicine

PO08.01 Development of In-house Travel Medicine Services for a Large Multinational Corporation
A. Trausch1, T. Wright1
1Advocate Health Care, Occupational Health, Lake Zurich, United States, 2W. W. Grainger, Inc, Health Services, Lake Forest, United States

PO08.02 First Approach on Global Occupational Health and Travel Medicine Care Reporting Inside a Multinational Company
S. Esser
International SOS, Central Europe Medical Department, Neu-Isering, Germany

PO08.03 Paederus Dermatitis: Also an Offshore Problem? - Cases from Equatorial Guinea
M. Felfernig1, J. Teletxea2, B. Dees3
1International SOS, MS-Middle East, Nigeria and Equatorial Guinea, Dubai, United Arab Emirates, 2International SOS, MS-Nigeria, Equatorial Guinea, Bata, Equatorial Guinea, 3International SOS, MS-EECA and OH, Dubai, United Arab Emirates

67
PO08.04
Body System Involved in Case Presentations on Offshore Installations - Is There a Difference between West Africa and Middle East? - A Preliminary Report
S. Ibrahim, A. Nosa, B. Dees, M. Felfernig
International SOS, Middle East, Dubai, United Arab Emirates, 1International SOS, Nigeria, Port Harcourt, Nigeria, 1International SOS, ECEA and OH, Dubai, United Arab Emirates, 1International SOS, Middle East, Nigeria and Equatorial Guinea, Dubai, United Arab Emirates

PO08.05
Extreme Long-Term Exposure to Fresh Water and Soil in the DRC: Active Screening Results for the Detection of Acute Schistosomiasis and Strongyloidiasis from two BE Military Cohorts.
P. Soentjens, A. Aerssens, B. Damanet, P. Andries, A. Wauters, L. Cnops, M. Van Esbroeck
Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, 1Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO08.06
Initial Neutralising Antibody Response to 3 or 4 Rabies Intradermal Pre-exposure Vaccination: Is There a Difference? A Single-Center Retrospective Analysis
P. Soentjens, B. Damanet, P. Andries, B. Hennion, C. Arnould, A. Aerssens
Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, 1Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

Pre-travel Advice and Approaches; Risk assessment/communication

PO09.01
A Pilot Study on Testing the Effect of HIV Information
G. Haile, L. Heier, G. Bjune
Reiseklinikken - Oslo Travel clinic, Oslo, Norway, 1University of Oslo, Dept. of Biology, Oslo, Norway, 3University of Oslo, Institute of Health and Society, Faculty of Medicine, Oslo, Norway

PO09.02
Evaluating the Effectiveness of the Pre-travel Visit
J. Richards, N. Masunaga
Vaden Health Center, Stanford University, Menlo Park, United States, 2Vaden Health Center, Stanford University, Stanford, United States

PO09.03
Which Anti-Malarial? Analysing the Complexities and Variables Involved in Making Safe and Effective Recommendations to Travellers
A. Willcox, H. Chera, G. Hewitt, A. Halliday
Health Team Ltd., Birmingham, United Kingdom

PO09.04
Travel Health Services Experience from a New Travel Clinic in Doha, Al Ahli Hospital, Doha, Qatar
A. Baxarwali
Al Ahli Hospital, Doha, Qatar

PO09.05
Travel Related Medications and their Interaction with Chronic Therapy: Highly Frequent and Easily Overlooked during Pre-travel Consultation
S. Stienlauf, B. Streitsh, E. Kopel, E. Meltzer, E. Leshem, D. Kurnik, G. Segal, E. Schwartz
The Sheba Medical Ctr, The Travel Clinic & the Center for Tropical Medicine, Tel Hashomer, Israel, 3The Sheba Medical Ctr, Departments of Internal Medicine, Tel Hashomer, Israel, 3Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, 3The Sheba Medical Ctr, The Arrow Project, Tel Hashomer, Israel

PO09.06
Communicating Flu Prevention Messages to US-Mexico Land Border Crossers: Lessons Learned
1Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, 2Oak Ridge Associate Universities/Oak Ridge Institute for Science and Education, Oak Ridge, United States
PO09.07
Knowledge, Attitudes and Practices Evaluation About Travel Medicine Counseling in Italian Customers of Pharmacies in Calabria, Italy
S. Neri¹, F. Foti²
¹Salus Pharmacy 'Dr. Neri Quintino', Reggio Calabria, Italy, ²La Feluca Travel Clinic, Reggio Calabria, Italy

PO09.08
Pre-travel Risk Discussion: How Many and Which Topics are Discussed in an Average Pre-travel Consultation?
M. Croughs¹,², A. de Gouw¹
¹GGD Hart voor Brabant, Travel Clinic, 's-Hertogenbosch, Netherlands, ²Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO09.09
HIV Post Exposure Prophylaxis Following Sexual Exposure: A Missed Opportunity for Intervention during the Pre-travel Consultation?
D. Brawley¹, A. Rea²
¹Sandyford, Glasgow, United Kingdom

PO09.10
What Needs to Prepare for a Long Flight to Asia? - Lessons Learned from an Emergency Landed Case with Acute Exacerbation of Chronic Renal Failure
S. Otsu¹, S. Yamaji²
¹Japanese Red Cross Wakayama Medical Center, Wakayama City, Japan

PO09.11
Pre-travel Consultations in a Travel Clinic: An Opportunity for Interprofessional Education
S. Seed¹, K. Sullivan¹, K. Dunican¹, L. Spooner¹, K. O'Connor², G. Abraham³
¹MCPHS University, Pharmacy Practice, Worcester, United States, ²Saint Vincent Hospital, Ambulatory Care Clinic, Worcester, United States, ³Saint Vincent Hospital, Medicine, Worcester, United States

PO09.12
Seroprevalence of Hepatitis A in Argentine Travelers and Cost-saving Analyses of Two Preventive Strategies
A. Macchi¹, C. Biscayart¹, V. Verdaguer¹, P. Elmassian¹, M.R. Tisi Bana², M.L. Strada¹, M. Dalbosco¹, D. Stamboulian¹
¹División Medicina del Viajero, Stamboulian Servicios de Salud, Buenos Aires, Argentina, ²Internal Medicine Department, Hospital Universitario Austral, Pilar, Argentina

PO09.13
A Report on Travel and Vaccination Patterns over a 5 Years Period from a Travel Clinic in Northern Italy
M. Migliorini¹, F. Marchiori¹, D. Berti¹, F. Tognon¹, S. Tardivo¹, F. Gobbi², A. Rossanese³
¹University of Verona, Dept. of Public Health, Verona, Italy, ²Sacro Cuore-Don Calabria Hospital, Centre for Tropical Diseases, Negrar, Verona, Italy

PO09.14
Can You Understand Me Now? Online Focus Group Testing of Travel Health Messages for Clear Communication
A.W. Lee¹, S. Erskine¹, C. Brown², B. Wilburn², K. Holton¹
¹Centers for Disease Control and Prevention, Travelers' Health Branch, Division of Global Migration and Quarantine, Atlanta, United States, ²Oak Ridge Associated Universities, Health Communication and Technical Training, Oak Ridge, United States

P9.15
You Want Me To Do What? A Qualitative Analysis of the Feasibility of Travel Health Recommendations
K. Holton¹, A.W. Lee¹, S. Erskine¹, C. Brown⁵, B. Wilburn²
¹Centers for Disease Control and Prevention, Travelers' Health Branch, Atlanta, United States, ²Oak Ridge Associated Universities, Health Communication and Technical Training, Oak Ridge, United States

PO09.16
Travel Health: Perceptions and Practices of Travel Agents in London
E.L. Pine¹
¹RCPSG, Glasgow, United Kingdom
PO09.17
Promoting Diphteria, Acellular Pertussis, Tetanus, Polio (DaPTP) Booster Vaccination instead of Diphteria/Tetanus/Polio (DTP) Booster Vaccination to Travelers to Protect during and post Travel: A Retrospective Analysis in Dutch Travel Clinics
P.A. de Beer1,2, H.A. Caris2
1Medical Services for the Tropics, Maastricht, Netherlands, 2365-Center for Infection Prevention (CIP) and Travel Clinics, Utrecht, Netherlands

PO09.18
To Notify or Not To Notify: Agency Perspectives on the Development of Travel Health Notices
K.E. Spruit-McGoff1, J. Geduld2, D. Jermacane9, C.V. Lee1, R. Henry1, M. Crawley O'Sullivan1, K. Holton1, G. Brunette1, C. Brown3
1Centers for Disease Control and Prevention, Travelers Health Branch, Atlanta, United States, 2Public Health Agency of Canada, Ottawa, Canada, 3National Travel Health Network and Centre, London, United Kingdom, 4Centers for Disease Control and Prevention, Atlanta, United States

PO09.19
Overview of 1749 Travelers Visiting the AMC Center of Travel Medicine from July 2011 to July 2012
R.W. Wieten1, M.R. van der Schalie1, C. Stijnis1, P.P.A.M. van Thiel1, A. Goorhuis1, M. van Vuigt1, M.P. Grobusch4
1Academic Medical Center/University of Amsterdam, Center of Tropical and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam, Netherlands

PO09.20
Travel Agents and Travel Health Promotion: A Study in the Local Health Authority Lucca
R. Banducci1, G. Piamini1, D.R. de Wet1, A. Tomasi1, K. Farmer1
1University of Pisa, Hygiene and Preventive Medicine, Pisa, Italy, 2University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy, 3AUSL 2 Lucca, Department of Prevention, Lucca, Italy, 4St. George's University, Microbiology, St. George, Grenada

PO09.21
The Emergency Department as a Venue for Pre-travel Prophylaxis and Advice
R. Partridge1,2, L. Proano1
1Warren Alpert Medical School of Brown University, Department of Emergency Medicine, Providence, United States, 2Emerson Hospital, Department of Emergency Medicine, Concord, United States

PO09.22
Does Pre-travel Self Assessment of Risk Reduce Adverse Events during Medical Electives?
H.C. Bond1, S.F. Raffe1, K. Smith1, M.L. Schmid1
1Royal Victoria Infirmary, Infection & Tropical Medicine, Newcastle upon Tyne, United Kingdom, 2University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, United Kingdom

PO09.23
The Use of SOAP in Pre-travel Advice
O. Olatunde6
6Dalhousie University, Family Medicine, Moncton, Canada

PO09.24
Development of the Scottish Malaria Advisory Group 2012
L. Boyne1, C. Doherty2, F. Genasi3, M. Jones4, A. MacConnachie4, F. Marra5, C. Redman1, K. Smith1, H. Sutton1, M. Umeed5
1Health Protection Scotland, Travel and International Health Team, Glasgow, United Kingdom, 2Royal Hospital for Sick Children, Yorkhill, Paediatric Infectious Disease, Glasgow, United Kingdom, 3Western General Hospital, Regional Infectious Diseases Unit, Edinburgh, United Kingdom, 4Gartnavel General Hospital, Brownlee Infectious Diseases Unit, Glasgow, United Kingdom, 5Brownlee Infectious Diseases Unit, Pharmacy, Glasgow, United Kingdom, 6General Practice, Specialist Nurse Practitioner, Glasgow, United Kingdom

PO09.25
Economics of Malaria Prevention in United States Travelers to West Africa
1CDC, DGMQ Policy Team, Atlanta, United States, 2CDC, DGMQ, Atlanta, United States, 3CDC, DPDM, Atlanta, United States, 4University of Massachusetts Medical School, Department of Quantitative Health Sciences, Worcester, United States, 5Bedford MA Medical Center, Center for Health Quality, Outcomes, and Economics Research, Bedford, United States, 6Massachusetts General Hospital, Division of Infectious Diseases, Boston, United States, 7Harvard Medical School, Department of Medicine, Boston, United States, 8CDC, DPEI, Atlanta, United States
Abstracts - Poster Presentations

Professional Education and Training

PO10.01
Membership Examination of the Faculty of Travel Medicine (Royal College of Physicians and Surgeons of Glasgow) - Part 2 Objective Structured Clinical Examination
L. Boyne1, E. Anderson2, L. Bramham3, P.L. Chiodini4, G. Flaherty5, A. Green6, A. Grieve1, V. Hogg7, M. Jones8, A. McDonald1, A.W. Todd1
1Royal College of Physicians and Surgeons Glasgow, Faculty of Travel Medicine, Glasgow, United Kingdom, 2NH Edinburgh, United Kingdom, 3Health Protection, Public Health Protection, Glasgow, United Kingdom, 4MASTA, Leeds, United Kingdom, 5Hospital for Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, 6National University of Ireland, School of Medicine, Galway, Ireland, 7Royal Centre for Defence Medicine, Infection Prevention and Control, Birmingham, United Kingdom, 8Royal College of Physicians and Surgeons Glasgow, Department of Examinations, Glasgow, United Kingdom, 9Western General Hospital, Regional Infectious Diseases Unit, Edinburgh, United Kingdom

PO10.02
Information Overload or News You Can Use: How Nurses View Travel Immunization Resources
G. Rosse1ot1, E. Rosenblatt2, American Travel Health Nurses Association Board of Directors
1Travel Well of Westchester, Inc., Briarcliff Manor, United States, 2University of Wisconsin Medical Foundation, Madison, United States

PO10.03
Travel Health and Cultural Awareness of Short Term Volunteers Providing Healthcare in Honduras
K. Avery1, L. Kennedy Sheldon2, R. Martin2
1Mount Auburn Hospital, Cambridge, United States, 2University of Massachusetts, Boston, United States

PO10.04
Delegated Tasks and Quality Control in the Collaboration of Nurses and Physicians Active in Travel Clinics in the Netherlands
P.A. de Beer1,2, H.A. Caris3
1Medical Services for the Tropics Maastricht, Travel Clinics, Maastricht, Netherlands, 2365-Center for Infection Prevention (CIP) and Travel Clinics, Utrecht, Netherlands, 3365-Center for Infection Prevention (CIP) and Travel Clinics, Utrecht, Netherlands

PO10.05
Improving Travel Medicine Education at a Multi-disciplinary US Healthcare Company
S.A. McDevitt1, D. Keane2
1Walgreens - Take Care Health Systems, Product Solutions, New York, United States, 2Walgreens - Take Care Health Systems, Corporate Health, New York, United States

PO10.06
The Travel Health Advisory Group, Australia: A Joint Travel Industry and Travel Health Special Interest Group Promoting Healthy Travel
P.A. Leggat1, Travel Health Advisory Group, Australia
1James Cook University, Discipline of Public Health and Tropical Medicine, Townsville, Australia

Returning Travellers

PO11.01
The Risk Factors of the Colonization of Extended-Spectrum β-Lactamase Producing Escherichia coli in the Stools of Returning Japanese Travelers: A Retrospective Case-Control Study
K. Yaita1, T. Suzuki1, Y. Yoshimura1, N. Tachikawa1
1Yokohama Municipal Citizen’s Hospital, Division of Infectious Diseases, Yokohama, Japan

PO11.02
Schistosomiasis among Returned Travellers: A Continuing Underestimated Condition
A. Goorhuis1, A. Bart2, T. van Gool1, M. van Vugt1, C. Stijnis2, M.P. Grobusch1, P.P. van Thiel2
1Academic Medical Center, Infectious Diseases and Tropical Medicine, Amsterdam, Netherlands, 2Academic Medical Center, Parasitology, Amsterdam, Netherlands
PO11.03  
Suggestive Paradoxical Reactions after Treatment with Praziquantel in Two Asymptomatic Travelers with Chronic Stage of Schistosomiasis  
P. Soentjens\textsuperscript{1,2}, A. Aersens\textsuperscript{1}, E. Bottieau\textsuperscript{2}  
\textsuperscript{1}Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, \textsuperscript{2}Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO11.04  
Seroprevalence of Schistosomiasis in Scottish School Groups Returning from Sub-Saharan Africa  
C.C. Smith\textsuperscript{1}, C. Redman\textsuperscript{1}, F. Genasi\textsuperscript{1}  
\textsuperscript{1}Health Protection Scotland, Travel and International Health, Glasgow, United Kingdom

PO11.05  
Acute Schistosomiasis: A Risk Underestimated by Travelers and a Diagnostic Challenge for Medical Practitioners  
L. Rochat Stettler\textsuperscript{1}, A. Bizzini\textsuperscript{2}, N. Senn\textsuperscript{3}, P.-Y. Bochu\textsuperscript{4}, S. de Vallière\textsuperscript{5}  
\textsuperscript{1}University Hospital, Travel Clinic, Department of Ambulatory Care and Community Medicine, Lausanne, Switzerland, \textsuperscript{2}University Hospital, Division of Infectious Diseases, Lausanne, Switzerland, \textsuperscript{3}University Hospital, Department of Ambulatory Care and Community Medicine, Lausanne, Switzerland

PO11.06  
Diagnosis of Travel-related Schistosoma mansoni Infection in a Cohort of 21 Subjects  
P. Soentjens\textsuperscript{1,2}, L. Cnops\textsuperscript{1}, W. Peetermans\textsuperscript{3}, R. Mertens\textsuperscript{4}, J. Van der Hilst\textsuperscript{5,6}, A. Van Gompel\textsuperscript{1}, E. Van Wijngaarden\textsuperscript{1}, M. Van Estbroeck\textsuperscript{1}  
\textsuperscript{1}Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium, \textsuperscript{2}Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, \textsuperscript{3}Internal Medicine, Universitair Ziekenhuis Leuven, KU Leuven, Leuven, Belgium, \textsuperscript{4}Vrije Universiteit Brussel, Internal Medicine - Infectology, Brussels, Belgium, \textsuperscript{5}Jessa Hospital, Department of Infectious Diseases and Immunology, Hasselt, Belgium, \textsuperscript{6}University of Hasselt, BIOMED, Diepenbeek, Belgium

PO11.07  
Gastrointestinal Illnesses during and after Travel among Boston-Area International Travelers  
P.V. Han\textsuperscript{1}, L.H. Chen\textsuperscript{2,3}, M.E. Wilson\textsuperscript{4}, E.S. Jentes\textsuperscript{1}, C.M. Benoit\textsuperscript{5}, W.B. Macleod\textsuperscript{6,7}, R.J. Stoney\textsuperscript{1}, D.H. Hamer\textsuperscript{1,8}, E.D. Barnett\textsuperscript{5}  
\textsuperscript{1}Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, \textsuperscript{2}Mount Auburn Hospital, Travel Medicine Center, Cambridge, United States, \textsuperscript{3}Harvard Medical School, Boston, United States, \textsuperscript{4}Harvard School of Public Health, Global Health and Migration, Boston, United States, \textsuperscript{5}Boston Medical Center, Maxwell Finland Laboratory for Infectious Diseases, Boston, United States, \textsuperscript{6}Boston University, Center for Global Health and Development, Boston, United States, \textsuperscript{7}Boston University School of Public Health, International Health, Boston, United States, \textsuperscript{8}Boston University School of Medicine, Infectious Diseases, Boston, United States

PO11.08  
A Returning Traveller with Congo Crimean Haemorrhagic Fever: Challenges and Lessons  
A. MacConnachie\textsuperscript{1}, D. Barr\textsuperscript{1}, D. Bell\textsuperscript{1}, R. Fox\textsuperscript{1}, M. Jacobs\textsuperscript{1}, I. Cropley\textsuperscript{1}, S. Hopkins\textsuperscript{1}, N. Dawood\textsuperscript{2}, C. Aitken\textsuperscript{1}, C. Brown\textsuperscript{1}, T. Brooks\textsuperscript{1}, S. Ahmed\textsuperscript{1}, B. Jeffs\textsuperscript{1}  
\textsuperscript{1}Brownlee Infectious Diseases Unit, Glasgow, United Kingdom, \textsuperscript{2}Royal Free NHS London Foundation Trust, London, United Kingdom, \textsuperscript{3}West of Scotland Specialist Virology Centre, Glasgow, United Kingdom, \textsuperscript{4}Health Protection Agency, Porton Down, United Kingdom, \textsuperscript{5}Department of Public Health, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom

PO11.09  
Hepatitis A with Delayed Elevation in the Serum Hepatitis A Virus-specific Immunoglobulin M Antibody Titer: A Case Report and Literature Review  
J. Supiha\textsuperscript{1}, Y. Kato\textsuperscript{1}, K. Takahashi\textsuperscript{1}, Y. Yanagawa\textsuperscript{1}, M. Ujile\textsuperscript{1}, N. Takeshita\textsuperscript{1}, S. Kanagawa\textsuperscript{1}, N. Ohmagari\textsuperscript{1}, S. Mihira\textsuperscript{1}  
\textsuperscript{1}National Center for Global Health and Medicine, Disease Control and Prevention Center, Tokyo, Japan, \textsuperscript{2}Toshiba General Hospital, Department of Medical Sciences, Tokyo, Japan

PO11.10  
Diagnosis and Management of Travellers Returning from a Developing Country  
P. Zimmermann\textsuperscript{1}, K. Mühlethaler\textsuperscript{1}, H. Furrer\textsuperscript{1}  
\textsuperscript{1}University Hospital, Department of Infectious Diseases, Bern, Switzerland
PO11.11
Common-sense Interpretation and Application of An International Treaty: Applying International Health Regulations At Points of Entry
C.A. Redman1, J. Hart2, A. Wilson3, N. Black4, K. Smith5
1Health Protection Scotland, Glasgow, United Kingdom, 2Public Health Wales, Mold, United Kingdom, 3Public Health Agency Northern Ireland, Belfast, United Kingdom, 4Health Protection Agency, Newcastle, United Kingdom, 5Health Protection Scotland, Medical Lead - Travel Health, Glasgow, United Kingdom

P11.12
Leishmaniasis Acquired by Travellers to Endemic Regions in Europe - a EuroTravNet Multi-Centre Study
J.P. Cramer1,2, U. Ehehalt1, M. Schunk3, M. Jensenius4, P.J.J. van Genderen5, E. Gkrania-Klotsas6, F. Chappuis7, P. Schlagenhauf8, R. Lopez-Velez9, P. Parola10, G.D. Burchard11
1University Medical Center Hamburg-Eppendorf (UKE), Section Tropical Medicine, Hamburg, Germany, 2Bernhard Nocht Institute for Tropical Medicine (BNITM), Clinical Research, Hamburg, Germany, 3Ludwig-Maximilians University of Munich, Department of Infectious Diseases and Tropical Medicine, Munich, Germany, 4Oslo University Hospital and University of Oslo, Department of Infectious Diseases, Oslo, Norway, 5Harbor Hospital, Institute for Tropical Diseases, Rotterdam, Netherlands, 6Addenbrooke’s Hospital, Department of Infectious Diseases, Cambridge, United Kingdom, 7Geneva University Hospitals and University of Geneva, Geneva, Switzerland, 8University of Zurich Centre for Travel Medicine, Division of Epidemiology and Communicable Disease, Institute for Social and Preventive Medicine, Zurich, Switzerland, 9Hospital Universitario Ramón y Cajal, Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Madrid, Spain, 10Aix-Marseille-Université and Assistance Publique-Hôpitaux de Marseille, University Hospital Institute in Infectious Diseases, Tropical Medicine Unit, Marseille, France

PO11.13
Melioidosis: A Case Report in a Returning Traveler from Singapore
S. Amadas1, S. Dal Zoppo1, L. Signorini1, F. Castelli1
1University Division of Tropical Medicine and Infectious Diseases, Brescia, Italy

PO11.14
HIV and Hepatitis A, B and C Screening in Patients Admitted with Imported Malaria
A.S. Santos1,2, C. Abreu1,2, A. Sarmento1,2
1Hospital S João, Infectious Diseases, Porto, Portugal, 2Medical School, Porto, Portugal

PO11.15
Usefulness of Influenza Rapid Diagnostic Tests for the Management of Travellers Returning with Fever: a Randomized Controlled Study
D. Berthod1,2, B. Genton1,2,3, J. Blum4, C. de Vallière5
1Travel Clinic, Department of Ambulatory Care and Community Medicine, University Hospital, Lausanne, Switzerland, 2Division of Infectious Diseases, University Hospital, Lausanne, Switzerland, 3Swiss Tropical and Public Health Institute, Basel, Switzerland

PO11.16
Medical Tourism: Infection with Acid Fast Bacteria after Cosmetic Breast Surgery in India
C.D. Vinnemeier1, A. Wawrzyniak1, G.D. Burchard1,2, S. Schmiedel1, J.P. Cramer1
1University Medical Center Hamburg-Eppendorf (UKE), Section Tropical Medicine, Hamburg, Germany, 2Bernhard Nocht Institute for Tropical Medicine (BNITM), Tropical Medicine, Hamburg, Germany

PO11.17
Infections in Returning Travellers to Vancouver/Victoria BC Tropical Medicine Group
W.G. Ghesquier1, P. Doyle2, Y. Mirzanejad3, M. Imperial4, M. Payne5, Tropical Medicine Group, BC
1Vancouver Island Health Authority, University of British Columbia, Medicine, Division of Infectious Diseases, Victoria, Canada, 2Vancouver General Hospital, University of British Columbia, Vancouver, Canada, 3Fraser Health Authority, University of British Columbia, Surrey, Canada, 4University of British Columbia, Vancouver, Canada

PO11.18
Travel-associated Primary Skin Melioidosis
J.F. Beert1, B. De Smet2, E. Van den Enden2, P. Wattiaux2, J. Steenbergen1, M. Stalpaert1, F. Van Gompel2, J. Jacobs3, E. Vlieghe4
1Algemeen Medisch Laboratorium, Department of Microbiology, Antwerp, Belgium, 2Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium, 3Highly Pathogenic & Foodborne Zoonoses, Veterinary and Agrochemical Research Center, Brussels, Belgium
PO11.19 Occurrence of Pulmonary Complications in Murine Typhus May Be Associated with Geographic Region
T.W. van der Vaart1, M. van Vugt1, C. Stijnis1, M.P. Grobusch1, P.P. van Thiel1, A. Goorhuis1
1Academic Medical Center/ University of Amsterdam, Infectious Diseases and Tropical Medicine, Amsterdam, Netherlands

PO11.20 NS1 Antigen Testing for the Diagnosis of Dengue in Returned Israeli Travelers
I.N. Fuchs1, H. Bin1, S. Schlesinger2, E. Schwartz3
1The Pediatric Infectious Disease Unit, Soroka University Medical Center, Ben-Gurion University, Beer Sheva, Israel, 2National Center for Zoonotic Viruses, Central Virology Laboratory, Ministry of Health, Public Health Services, Sheba Medical Center, Tel Hashomer, Israel, 3Center for Geographic Medicine and Tropical Diseases Sheba Medical Center, Tel Hashomer, Israel

PO11.21 Dengue Fever in Travelers from a Non Endemic Country
C. Perret1; E. Balcells1, C. Vizcaya1, T. Hirsch1, T. Azócar2, C. Martínez2, L. Montecinos3, M. Ferrés1
1Pontificia Universidad Católica de Chile, School of Medicine, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Virology Laboratory, Santiago, Chile

Trauma, Injury, Security

PO12.01 Studies on Anti-inflammatory, Anti-oxidant and Wound Healing Properties of the Tea Fungus, Kombucha
J.A. Ofori1, G.A. Larbie1, P. Addo2, A. Ocloo1, M.F. Ofori3, W.S.K. Gbewonyo1
1University of Ghana, Biochemistry, Cell and Molecular Biology, Accra, Ghana, 2Noguchi Memorial Institute for Medical Research, Animal Experimentation, Accra, Ghana, 3Noguchi Memorial Institute for Medical Research, Immunology, Accra, Ghana

Travel Medicine Practice

PO13.01 The Certificate of Fitness to Fly
V. Mera1, L. Cebrián2
1Clinica Benidorm, Internal Medicine, Benidorm, Spain, 2Clínica Británica, Travel Medicine, Calpe, Spain

PO13.02 Epidemiological Characteristics of Long-Term Travelers Around the World in Kurume University Hospital, Japan
H. Hidaka1, H. Watanabe1
1Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, Kurume, Japan

PO13.03 Travel Medicine in Mexico - First Clinic
D.A. Rivera-Avila1, X. Vite-Velázquez1, I. Cortes-Tapia1, L.M. Uribe-Castro1, P.A. Reyes1, B. Díaz-Ramírez1
1Clínica de Atención Preventiva del Viajero, UNAM, Research Division, Mexico City, Mexico

PO13.04 What Kind of Clients Should Be Targeted On? Seven-month Experience of a Brand New Travel Clinic in Japan
M. Norizuki1, S. Iwamoto2, E. Kusumi2, Y. Morisawa1
1Jichi Medical University, Center for Clinical Infectious Diseases, Shimotsuke, Japan, 2Navitas Clinic Kawasaki, Kawasaki, Japan

PO13.05 Medical Specialty Impacts Delivery of Travel Medicine Services
P.W. Hickey1,2, D.C. Girasek1, M. Salisu1, T.D. Gleeson1
1Uniformed Services University, Preventive Medicine, Bethesda, United States, 2Uniformed Services University, Pediatrics, Bethesda, United States, 3Uniformed Services University, Internal Medicine, Bethesda, United States

PO13.06 ISTM Member Survey on Sustainable Tourism: A Preliminary Report
M.P. Muehlenbein1, G. Brink2, ISTM Destination Communities Support Interest Group
PO13.07
Assistance Medicine - A New Sub-Specialty in Travel Medicine - First Approach to Post-graduate Education and a Medical Curriculum in Germany
S. Esser1, K. Sickmann2
1International SOS, Central Europe Medical Department, Neu-Isenburg, Germany, 2Volkswagen AG, Medical Department, Wolfsburg, Germany

PO13.08
Travel Health Knowledge, Attitude and Practices among Zimbabwean Travellers
S.E.T. Mba1
1University of Zimbabwe, Harare, Zimbabwe

PO13.09
New and Emerging Hazards Surveillance; Travel Medicine Expertise applied in Health Protection
C.A. Redman1, F. Genasi1, H. Sutton1
1Health Protection Scotland, Glasgow, United Kingdom

PO13.10
Implementation of a Multidisciplinary Health Travel Program in the University of Campinas (UNICAMP) - Brazil
M.C.C. Del Monte1, I.D.C. Guerreiro1, M.H.P. Pavan1, P.A.T. Leme1, R.T. Mendes1, R.C.G. Trevisane1, T.M. Nieri1
1Universidade Estadual de Campinas, Campinas, Brazil

PO13.11
Compliance in Travel Medicine Consultation in Brazil: A Pilot Study
K.M.P. Rodrigues1, F.S.V. Martins1
1Universidade Federal do Rio de Janeiro, Cives (Centro de Informação em Saúde para Viajantes), Rio de Janeiro, Brazil

PO13.12
Evolution of the Pre Travel Consultations in the North of Portugal during the Period from 2002 to 2011
G. Saldanha1, S. Barbosa1, A. Silva1, I. Cruz1, A. Cardoso1, N. Rodrigues2, D. Antunes1
1Sanidade Internacional CVI Porto, Porto, Portugal, 2Sanidade Internacional CVI Matosinhos, Matosinhos, Portugal

PO13.13
Rethinking Standby Emergency Treatment for Malaria: Acute Respiratory Distress Syndrome Despite Treatment of Uncomplicated Malaria in Returned Travelers
K.R. Tan1, P.M. Arguin1
1Centers for Disease Control and Prevention, Atlanta, United States

Japanese Encephalitis

PO14.01
Long-Term Data on Cross-reactive Immunity after Primary and Booster Vaccinations against Japanese Encephalitis
E.O. Erää1,2, H. Hervius Asking1, S. Yoksan1, L. Rombo2,5, J. Riutta5, S. Vene7, L. Lindquist3, O. Vapalahti1,8,9, A. Kantele2,7,8
1Haartman Institute, University of Helsinki, Helsinki, Finland, 2Helsinki University Central Hospital, Division of Infectious Diseases, Department of Medicine, Helsinki, Finland, 7Karolinska Institutet, Department of Medicine, Unit for Infectious Diseases, Stockholm, Sweden, 8Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand, 9Centre for Clinical Research, Sörmland County Council, Eskilstuna, Sweden, 10Travel Clinic, Postitalo, Lääkärikeskus Aava, Helsinki, Finland, 11Swedish Institute for Communicable Disease Control, Solna, Sweden, 12HUSLAB, Division of Virology and Immunology, Helsinki University Central Hospital, Helsinki, Finland, 13University of Helsinki, Department of Veterinary Biosciences, Helsinki, Finland

PO14.02
Reduced Vaccination Rate against Japanese Encephalitis at a Norwegian Vaccination Clinic after Introduction of Ixiaro®
R. Raastad1, L. Heier1, G. Hasle1
1Oslo Travel Clinic, Oslo, Norway
PO14.03
Antibody Persistence in Children and Immunogenicity and Safety of a Booster Dose of the Inactivated Japanese Encephalitis Vaccine IXIARO®, IC51
K.L. Dubischar-Kastner¹, V. Kadlecak², B. Sablan Jr³, C.F. Borja-Tabora⁴, S. Gatchalian⁴, S. Eder⁵, K. Westritschnig⁶
¹Intercell AG, Vienna, Austria, ²University of the Philippines, Philippine General Hospital, Department of Pediatrics, Manila, Philippines, ³Research Institute for Tropical Medicine, Department of Health, Manila, Philippines, ⁴University of the Philippines, Manila, Philippines

PO14.04
Immunogenicity and Safety of the Inactivated Japanese Encephalitis Vaccine IXIARO®, IC51, in Elderly
K.L. Dubischar-Kastner¹, J.P. Cramer⁶, S. Eder⁵, T. Jelinek⁷, B. Jilma⁷, H. Kollaritsch⁸, E. Reisinger⁸, K. Westritschnig⁹
¹Intercell AG, Vienna, Austria, ²University Medical Center Hamburg-Eppendorf (UKE), Department of Internal Medicine, Section Tropical Medicine / Infectious Diseases, Hamburg, Germany, ³Berlin Center for Travel & Tropical Medicine, Berlin, Germany, ⁴Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria, ⁵Medical University Vienna, Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria, ⁶University of Rostock, Department of Tropical Medicine & Infectious Diseases, Rostock, Germany

PO14.05
Post-marketing Safety Profile of the Inactivated Japanese Encephalitis Vaccine IXIARO® - Experience Three Years after Launch
Z. Müller¹, K.L. Dubischar-Kastner¹, R. Hennig², K. Westritschnig¹
¹Intercell AG, Vienna, Austria, ²SCRATCH Pharmacovigilance GmbH, Butzbach, Germany

Rabies
PO15.01
Frequency of and Responses to Potential Rabies Exposures in Peace Corps Volunteers, 2011
K. Harvey¹, E.S. Jentes¹, M. Charles², B. Petersen³, K. Johnson¹, J. Blanton¹, M.J. Sotir¹, G. Brunette¹
¹Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, ²Peace Corps, Office of Medical Services, Washington, United States, ³Centers for Disease Control and Prevention, Division of High Consequence Pathogens and Pathology, Atlanta, United States

PO15.02
Immunogenicity of a Modified Intradermal Pre-exposure Rabies Vaccination Schedule Using a Purified Chick Embryo Cell Vaccine (Rabipur)
C. Lau¹, N. Hohi²,³
¹University of Queensland, Queensland Children's Medical Research Institute, Brisbane, Australia, ²Travel Medicine Alliance Clinics, Perth and Brisbane, Australia, ³Griffiths University, School of Medicine, Gold Coast, Australia

PO15.03
Rabies Post Exposure Consultations in New Zealand 1998-2012
M. Shaw¹, J.T. Visser², C. Edwards³
¹James Cook University, Townsville, School Public Health, Auckland, New Zealand, ²University of Otago, Primary Health Care & General Practice, Wellington, New Zealand

PO15.04
Young Short-Term Travelers are at Potential Risk of Rabies
E. Rowe¹, F. Dimatac³, C.J. Go¹, P.L. Lim¹
¹Tan Tock Seng Hospital, Infectious Diseases, Singapore, Singapore

PO15.05
Case Series of Animal Bites Obtained by Patients in a Japanese Hospital When They Were Abroad
N. Takeshita¹, Y. Kato¹, S. Kutsuna¹, M. Ujiie¹, K. Hayakawa¹, S. Kanagawa¹, N. Ohmagari¹
¹National Center for Global Health and Medicine, Disease Control and Prevention Center, Tokyo, Japan
A Comparative Study on Efficacy of Purified Chick Embryo Cell Rabies Vaccine (Rabipur®) as a Pre-exposure Prophylaxis for the Japanese, Administering Three Doses on Days 0, 7, 21 or 28 and Three Doses on Days 0, 30, 180

N. Mishima1, M.J. Yoshikawa, T. Shimono, Y. Nakatani1,2, H. Ishizaka2, M. Miyake1, S. Kanda1, T. Nishiyama1,2
1Kansai Medical University, Department of Public Health, Hirakata, Japan, 2Kansai Medical University Taki Hospital, Center for Travel Medicine, Moriyoshi, Japan, 3Kyoto University, Inter-Graduate School Unit for Sustainable Development and Survival Societies, Center for the Promotion of Interdisciplinary Education and Research, Kyoto, Japan

Yellow Fever

PO16.01
Yellow Fever Vaccination at Mexico’s Traveler Preventive Care Clinic - First Year
D.A. Rivera-Avila1, X. Vite-Velázquez1, I. Cortes-Tapia1, L.M. Uribe-Castro1, P.A. Reyes1, B. Diaz-Ramírez1
1Clínica de Atención Preventiva del Viajero, UNAM, Research Division, Mexico City, Mexico

Other Immunizations

PO17.01
From ‘Non-responders’ to ‘Poor-responders’ - Successful Use of Multi-site Intradermal Hepatitis B Vaccination
A.D. McCallum1, M.E. Jones1
1NHS Lothian, Regional Infectious Diseases Unit, Edinburgh, United Kingdom

PO17.02
A Double Dose Hepatitis B Vaccination Schedule in Travellers Presenting for Late Consultation
S.L. Hollenberg1, J. Wong1, M.K. Payne1
1University of British Columbia, Department of Family Medicine, Vancouver, Canada, 2University of British Columbia, School of Population and Public Health, Vancouver, Canada, 3University of British Columbia, Pathology and Laboratory Medicine, Vancouver, Canada

PO17.03
Meningococcal Vaccination Patterns of Travelers from Greece Visiting Sub-Saharan Africa
A. Pavli1, A. Spilioti1, P. Smet1, V. Silvestros2, F. Antoniadou2, A. Gregoraki2, H. Maltezou2
1Hellenic Centre for Disease Control and Prevention, Travel Medicine Office, Athens, Greece, 2Hellenic Centre for Disease Control and Prevention, Department for Interventions in Health Care Facilities, Athens, Greece, 3Regional Department of Public Health and Social Welfare, Athens, Greece

PO17.04
Antibody Persistence 4 Years after a Single Dose of a Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Adolescents and Adults
C. Borja-Tabora1, C. Montalban1, Z.A. Memish1, Y. Blanco1, M. Van der Wielen1, J.M. Miller3
1Research Institute for Tropical Medicine, Muntinlupa City, Philippines, 2Philippine General Hospital, Manila, Philippines, 3College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia, 4GlaxoSmithKline Vaccines, Wavre, Belgium, 5GlaxoSmithKline Vaccines, King of Prussia, United States

PO17.05
The First Norovirus Bivalent GI.1/GII.4 Virus-like Particle (VLP) Vaccine in Man
P. Mendelman1, J. Trenan2, S. Frey2, R. Gormley2, R. Atmar2, D. Topham2, W. Chen3, J. Ferreia3, R. Bargarthe1, C. Richardson3
1Takeda Pharmaceuticals Inc, Vaccines, Bozeman, United States, 2University of Rochester Medical Center, Rochester, United States, 3Saint Louis University School of Medicine, Saint Louis, United States, 4Naval Medical Research Center, Silver Springs, United States, 5Baylor College of Medicine, Houston, United States, 6University of Maryland School of Medicine, Baltimore, United States, 7The EMMES Corporation, Rockville, United States

PO17.06
Factors Determining the Uptake of MMR Vaccination among Korean International Travelers: Focus on Measles Outbreaks in Europe
S.Y. Shin1
1Korea Medical Institute, Seoul, Korea, Republic of

PO17.07
Hepatitis A Serologic Screening in Travellers: An evaluation 10 years after
B. Ngo1, R. Cartuvelis, K. Mazeran1, I. Geysens2, J. van der Has2, A. Mewis1
1JESSA Hospital, Laboratory Medicine, Hasselt, Belgium, 2JESSA Hospital, Infectious Diseases, Hasselt, Belgium
PO17.08
Hepatitis A Vaccination Coverage and International Travel among US-born and Foreign-born Adults
T.J. Cunningham, J.A. Singleton, T.V. Murphy, C.M. Brown, G. Brunette
1Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, United States,
2Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, United States,
3Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, United States,
4Travelers’ Health Branch, Centers for Disease Control and Prevention, Atlanta, United States

PO17.09
Influenza Vaccination Uptake among Australian Hajj Pilgrims in 2011
O. Barasheed, H. Rashid, L. Ridda, L. Heron, D. Dwyer, R. Booy
1National Centre for Immunisation Research and Surveillance, Westmead, Australia,
2The University of Sydney, Sydney Medical School, Sydney, Australia,
3The University of Sydney, Sydney Emerging Infections and Biosecurity Institute, Sydney, Australia,
4Westmead Hospital, Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia

Dengue

PO18.01
Dengue Surveillance by Proxy: Travellers as Sentinels for Outbreaks in the Pacific Islands
C. Lau, P. Weinstein, D. Slaney
1University of Queensland, Brisbane, Australia,
2Travel Medicine Alliance Clinics, Perth and Brisbane, Australia,
3University of South Australia, Barbara Hardy Institute, Adelaide, Australia,
4Institute of Environmental Science and Research, Porirua, New Zealand

PO18.02
Dengue Virus Infection in Bali, Indonesia: A Continued Challenge to a Tropical Tourist Destination
M.J. Yoshikawa, R. Kusriastuti, A. Suwandono, N. Mishima, T. Nishiyama
1Kyoto University, Center for the Promotion of Interdisciplinary Education and Research, Inter-Graduate School Unit for Sustainable Development and Survivable Societies, Kyoto, Japan,
2Ministry of Health, Directorate General of Disease Control and Environmental Health, Vector Borne Disease Control, Jakarta, Indonesia,
3Diponegoro University, School of Public Health, Semarang, Indonesia,
4Ministry of Health, National Institute of Health Research and Development, Jakarta, Indonesia,
5Kansai Medical University Takii Hospital, Center for Travel Medicine, Hirakata, Japan,
6Kansai Medical University, Department of Public Health, Hirakata, Japan

PO18.03
Intended Mosquito Avoidance Practices International Travel Behavior Model (IMAP-ITB) for Dengue Prevention in U.S. Travelers
K.C. Allen
1Kent State University, College of Public Health, Kent, United States

PO18.04
Half Century of Dengue in Thailand
1National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand,
2Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand,
3Department of Statistics, Faculty of Commerce and Accountancy, Chulalongkorn University, Bangkok, Thailand

PO18.05
Identification of High Risk Areas for DHF in Thailand
1National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand,
2Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand,
3Department of Statistics, Faculty of Commerce and Accountancy, Chulalongkorn University, Bangkok, Thailand
PO18.06
High Prevalence Rate of Previous Dengue Virus Infection among First Generation Surinamese Immigrants in The Netherlands
F.W. Overbosch1, A. van den Hoek1,2, J. Schinkel1, G.J. Sonder1,2,4
1Public Health Service (GGD), Department of Infectious Diseases, Amsterdam, Netherlands, 2Academic Medical Center, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands, 3Academic Medical Center, Department of Medical Microbiology, Section of Clinical Virology, Amsterdam, Netherlands, 4National Coordination Centre for Traveller’s Health Advice (LCR), Amsterdam, Netherlands

Malaria
PO19.01
An Unusual Case of Non-Falciparum, Non-Vivax Malaria in Singapore Presenting as Dengue Fever
R.K.C. Fong1
1Changi General Hospital, Department of Medicine, Division of Infectious Diseases, Singapore, Singapore

PO19.02
Malaria Prevention Strategies: Adherence among Boston-Area Travelers Visiting Malaria-endemic Countries
R.J. Stoney1, L.H. Chen2,3, E.S. Jentes3, M.E. Wilson4, P.V. Han5, C.M. Benoit6, W. Macleod7,7, D.H. Hamer6,7,8, E.D. Barnett1, Boston Area Travel Medicine Network
1Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, 2Mount Auburn Hospital, Travel Medicine Center, Cambridge, United States, 3Harvard Medical School, Boston, United States, 4Harvard School of Public Health, Global Health and Migration, Boston, United States, 5Boston Medical Center, Maxwell Finland Laboratory for Infectious Diseases, Boston, United States, 6Boston University, Center for Global Health and Development, Boston, United States, 7Boston University School of Public Health, International Health, Boston, United States, 8Boston University School of Medicine, Infectious Diseases, Boston, United States

PO19.03
Travel-related Cases of Malaria in Quebec, Canada
Y.G. Bui1,2,3, S. Trépanier4, M. Blackburn1,3, F. Milord1,3, É. Levac3
1Université de Sherbrooke, Public Health, Longueuil, Canada, 2Institut National de Santé Publique Du Québec, Montreal, Canada, 3CSSS Champlain-Charles-Lemoyne, Public Health, Longueuil, Canada, 4CSSS Manicouagan, Public Health, Baie-Comeau, Canada

PO19.04
Primaquine Use as the Anti-Malarial Relapse Drug in Japan - Possible Relevance of Body Weight-adjusted Doses to the Drug Efficacy
S. Shimizu1, T. Kikuchi1, M. Koga1, H. Maruyama2, M. Kimura3
1Department of Infectious Diseases and Applied Immunology, Research Hospital of the Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2Department of Infectious Diseases, Division of Parasitology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan, 3Department of Internal Medicine, Shin-Yamanote Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan

PO19.05
Efficacy and Tolerance of 420 mg Primaquine Radical Cure in Plasmodium vivax Relapses in a Series of Adult French Travelers
C. Rapp1,2,3, S. Ngo2, C. Ficko2, C. Plateau3, N. Cardon2, O. Aoun3, D. Andriamanantena3, M. Borne Pons3
1Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, 2Ecole du Val de Grâce, Paris, France, 3Begin Military Hospital, Saint-Mandé, France

PO19.06
Hemolytic Anemia Complicating Intravenous Artesunate Treatment in Severe Plasmodium falciparum Malaria: Stay Alert!
C. Rapp3,4, C. Ficko2, C. Plateau2, D. Andriamanantena3, O. Aoun3, J. Henard3
3Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, 4Ecole du Val de Grâce, Paris, France, 5Begin Military Hospital, Saint-Mandé, France

PO19.07
Severe Imported Adults P. falciparum Malaria: Clinical Spectrum and Outcome in 119 Cases
2Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, 3Ecole du Val de Grâce, Paris, France, 4Begin Military Hospital, Saint-Mandé, France
PO19.08
Prognostic Relevance of Conjugated Hyperbilirubinemia in Adults Presenting with Imported Plasmodium falciparum Malaria
C. Rapp1, C. de Moreuil1, C. Verret2, C. Ficko3, O. Aoun3, D. Andriamanantena4, C. Flateau3, P. Imbert3
1Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, 2Ecole du Val de Grâce, Paris, France, 3Begin Military Hospital, Saint-Mandé, France, 4CESPA, Paris, France

PO19.09
Detection of Antimalarial Drug Resistance: A Novel and Simple Real-time Sensitivity Assay for Plasmodium falciparum
M. Rebelo1, C. Tempera1, C. Sousa1, M.P. Grobusch2, T. Hanscheid3
1Instituto de Medicina Molecular, Lisboa, Portugal, 2Center for Tropical Medicine and Travel Medicine Department of Infectious Diseases, Division of Internal Medicine Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

PO19.10
Outbreak of Plasmodium falciparum and Ovale Infections in Belgian Military Personnel during and after Deployment in Kindu, DRC
P. Soentjens1, A. Wauters1, P. Andries1, B. Damanet1, W. Heuninckx2, M. Van Esbroeck1, A. Aerssens1
1Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, 2Institute of Tropical Medicine, Clinical Sciences, Antwerp, Belgium, 3Military Hospital Queen Astrid, Lab Department, Brussels, Belgium, 4Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO19.11
A Study of the Biting Pattern within Anopheles gambiae sensu latu (s.l.)
S.A. Pi-Bansa1, M. Appawu1, S. Dadzie1, K. Frempong1, J.H.N. Osei1,2, M. Wilson1, O. Danso2, D.A. Boakye1
1Noguchi Memorial Institute for Medical Research, Parasitology, Accra, Ghana, 2Kwame Nkrumah University of Science and Technology, Theoretical and Applied Biology, Kumasi, Ghana

PO19.12
Malaria Advice for India: Rational Use of Evidence With a Precautionary Approach
C.A. Redman1, L. Boyne1, F. Genasi1, M. Jones2, A. Macconnachie2, F. Marra2, C. Doherty2, C. Smith, H. Sutton1, M. Umeed1
1Health Protection Scotland, Glasgow, United Kingdom, 2Western General Hospital, Edinburgh, United Kingdom, 3Gartnavel General Hospital, Glasgow, United Kingdom, 4Yorkhill Hospital, Glasgow, United Kingdom, 5General Practice, Glasgow, United Kingdom

PO19.13
Syndrome of Inappropriate ADH Secretion (SIADH) in Severe Falciparum Malaria: Treatment with Vasopressin Receptor Antagonist (Vaptan)
S. Schmiedel1, G. Burchard1
1University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

PO19.14
Standby Emergency Treatment (SBET) for Presumptive Malaria: Use in U.S. Clinics Employing Nurse Educators
G. Rosselot1, G. Rosselot1
1Travel Well of Westchester, Inc., Briarcliff Manor, United States

PO19.15
Factors Associated with Imported Malaria Give Support to a State of ‘Long-Term’ Semi-immunity to Malaria in Sub-Saharan African Migrants Living in France
T. Pietroni1, A. Diallo1, M. Mechain1, M.-C. Receveur1, D. Malvy1,2
1University Hospital Center of Bordeaux, Travel Clinic and Division of Clinical Tropical Medicine, Department of Tropical Diseases, Bordeaux, France, 2Victor Segalen University, Centre René Labusquiére, Center for Tropical Medicine, Bordeaux, France

PO19.16
Multidisciplinary I.C.U. Management of Severe Plasmodium falciparum Malaria (S.P.F.M)
M.A. Sai1, F. Mwongera1
1Nairobi Hospital, Nairobi, Kenya
PO19.17 Malaria Prophylaxis Documented in 100 Expatriate Children in Western Africa - A Preliminary Report
M. Felfernig1, R. Ruthvin2
1International SOS, Dubai, United Arab Emirates, 2International SOS, Lagos, Nigeria

Other Vector-borne Infections

PO20.01 Detection of Leishmania siamensis DNA in Saliva by Polymerase Chain Reaction
A. Phumee1, K. Krivichian1, S. Chusri1, N. Noppakun1–2, A. Vibhagool2, V. Sanprasert2, H. Wilde3, P. Siriyasatien4,5
1Faculty of Medicine, Chulalongkorn University, Medical Science Program, Bangkok, Thailand, 2Faculty of Medicine, Chulalongkorn University, Department of Parasitology, Bangkok, Thailand, 3Faculty of Medicine, Prince of Songkla University, Department of Medicine, Songkhla, Thailand, 4Faculty of Medicine, Chulalongkorn University, Department of Medicine, Bangkok, Thailand, 5Bumrungrad International Hospital, Bangkok, Thailand

PO20.02 Occurrence of Chikungunya Virus in Field-caught Mosquitoes, Aedes albopictus, and Virological Feature of Patients with Suspected Chikungunya Fever in Thailand
U. Thavara1, J. Chompoosri1, P. Bhakdeenuan1, A. Phumee2, S. Anantapreecha3, S. Naemkhunthot1, S. Sangkhporn1, P. Siriyasatien2
1National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand, 2Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

PO20.03 Severe West Nile Virus Encephalitis in a Patient Repatriated from Djibouti
C. Rapp1,2, C. Ficko3, I. Leparc Goffard4, D. Andriamanantena5, C. Plateau6, O. Aoun6, C. Bigaillon6
1Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, 2Ecole du Val de Grâce, Paris, France, 3Begin Military Hospital, Saint-Mandé, France, 4CNR Arbovirus, Marseille, France

PO20.04 Heart Transplantation in Patient with Dilated Cardiomyopathy and Trypanosoma cruzi Positive Serology, in Bergamo, Italy
A. Raglio1, R. Fiocchi2, M. Verges3, F. Vallati4, M. Arosio1, G. Bargiggia1, A. Tebaldi1, C. Farina1
1AO Ospedali Riuniti, USC Microbiologia e Virologia, Dipartimento di Medicina di Laboratorio, Bergamo, Italy, 2AO Ospedali Riuniti, Dipartimento Cardiovascolare, Bergamo, Italy, 3Universidad de Barcelona, Departamento de Parasitologia, Barcelona, Spain, 4AO Ospedali Riuniti, USC Malattie Infettive, Bergamo, Italy

PO20.05 One Spray for All Biting Bugs? a Literature Review of Repellent Efficacy
E. Lupi1, C.F. Hatz1, P. Schlagenhauf1
1University of Zürich, Centre for Travel Medicine, Zürich, Switzerland

Older

PO21.01 Characterisation of Immune Responses to Primary Japanese Encephalitis Vaccination in Elderly Compared to Young Vaccinees
A. Wagner1, E. Garner-Spitzer1, J. Jasinska1, M. Paulke-Korinek1, M. Hofer1, H. Kollaritsch2, F.X. Heinz2, U. Wiedermann1
1Medical University of Vienna, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria, 2Medical University of Vienna, Department of Virology, Vienna, Austria

Immunocompromised

PO22.01 Yellow Fever Virus Neutralizing Antibodies Persist Despite Longstanding Immunosuppression
L.G. Visser1, A.W. de Visser1, E.F.F. Jonker2, D.K. Aalrink2
1Leiden University Medical Center, Travel Clinic, Department of Infectious Diseases, Leiden, Netherlands, 2Leiden University Medical Center, Department of Infectious Diseases, Leiden, Netherlands, 3KLM Health Services, Schiphol Oost, Netherlands
PO22.02
Risk Perception about Yellow Fever and Other Infectious Diseases among Travelers with HIV Followed at Hospital for Infectious Diseases Emilio Ribas, in Sao Paulo, SP, Brazil
L. Vieira1, J. Alves1
1Hospital for Infectious Diseases Emilio Ribas, Travel Medicine, Sao Paulo, Brazil

PO22.03
Immunocompromised Travelers from the U.S.: Demographic Characteristics, Travel Destinations, and Pre-travel Health Care from the U.S. Global TravEpiNet Consortium
B. Schwartz1, J. Rosen2, P. Han3, N.A. Hynes4, S.R. Raco5, E.S. Jentes5, R.C. LaRocque6, E.T. Ryan6, Global TravEpiNet Consortium
1Travel Medicine and Immunization Clinic, University of California, San Francisco, Division of Infectious Diseases, San Francisco, United States, 2Infectious Diseases and Travel Medicine Clinic, Georgetown University, Division of Infectious Diseases, Washington, United States, 3Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, 4Johns Hopkins Travel and Tropical Medicine Clinic, Johns Hopkins School of Medicine, Division of Infectious Diseases, Baltimore, United States, 5University of Massachusetts Medical School, Department of Quantitative Health Sciences, Bedford, United States, 6Traveler’s Advice and Immunization Center, Massachusetts General Hospital, Division of Infectious Diseases and Harvard Medical School, Boston, United States

PO22.04
Trends and Characteristics in HIV-infected and Diabetic Travelers Attending a Travel Clinic before Traveling to the (Sub)Tropics
F. Elfrink1,2, A. van den Hoek1,3, G. Sonder1,2,3
1Public Health Service (GGD), Department of Infectious Diseases, Amsterdam, Netherlands, 2National Coordination Centre for Traveller’s Health Advice (LCR), Amsterdam, Netherlands, 3Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and Aids, Academic Medical Center, Amsterdam, Netherlands

Infants/Young Children

PO23.01
Preparing Children for Travel to Developing Countries: A Survey of ISTM Pediatric Interest Group Members
J.C. Christenson1, P.R. Fischer2, S. Hagmann3, E. Leshem4,5, W. Stauffer6, E. Barnett7, ISTM Pediatric Interest Group
1Indiana University School of Medicine, Pediatric Infectious Diseases, Indianapolis, United States, 2Mayo Clinic Children’s Center, Rochester, United States, 3Albert Einstein College of Medicine, Bronx-Lebanon Hospital Center, New York, United States, 4Sheba Medical Center, Department of Internal Medicine C, Tel Hashomer, Israel, 5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 6University of Minnesota School of Medicine, Division of Infectious Diseases and International Medicine, Minneapolis, United States, 7Boston Medical Center, Maxwell Finland Laboratory for Infectious Diseases, Boston, United States

PO23.02
Characteristics of Pediatric Travelers Visiting a Travel Clinic at a University Hospital in Tokyo
S. Fukushima1, Y. Mizuno1, Y. Yamaguchi1, T. Hirohata1, S. Masuyama1, A. Hamada1
1Tokyo Medical University Hospital, Travellers’ Medical Center, Shinjuku, Japan

Other Special Needs Travellers

PO24.01
Evaluation of Bahaviour Influencing the Start of Malaria Chemoprophylaxis in 154 Travelers to Accra, Ghana
R.W. Wieten1, P.M.M. Biemond1, J.W.J. Kalule-Dusseldorp1, B.J. Visser1, P.P.A.M. van Thiel1, C. Stijnis1, A. Goorhuis1, M.P. Grobusch1, J. Harting2, M. van Vugt1
1Academic Medical Center/ University of Amsterdam, Center of Tropical and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam, Netherlands, 2Academic Medical Center/ University of Amsterdam, Department of Social Sciences, Amsterdam, Netherlands

PO24.02
Characteristics of Israeli Travelers with Chronic Illness Traveling to Tropical Countries
S. Stienlauf1,2,3, B. Streitskind4, E. Kopel1, E. Melzer5,6, E. Leshem7,8, D. Kurnik2,3, G. Segal2,3, E. Schwartz1,2,3
1The Sheba Medical Ctr, The Travel Clinic & the Center for Tropical Medicine, Tel Hashomer, Israel, 2The Sheba Medical Ctr, Departments of Internal Medicine, Tel Hashomer, Israel, 3Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, 4The Sheba Medical Ctr, The Arrow Project, Tel Hashomer, Israel
GlaxoSmithKline Satellite Symposium & Panel discussion

Monday, 20 May
13.00 – 14.30

Scientific Programme

Meningococcal Vaccination amongst the travel population

Chair: Ghassan Dbaibo

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00–13.10</td>
<td>Welcome and introduction</td>
<td>Ghassan Dbaibo</td>
</tr>
<tr>
<td>13.10–13.40</td>
<td>Quadrivalent conjugate vaccines in the adult and traveller population</td>
<td>Ghassan Dbaibo</td>
</tr>
<tr>
<td>13.40–14.00</td>
<td>Vaccination during outbreaks: recent lessons</td>
<td>Robert Steffen</td>
</tr>
<tr>
<td>14.00–14.20</td>
<td>Vaccinating travellers and pilgrims</td>
<td>Annelies Wilder-Smith</td>
</tr>
<tr>
<td>14.20–14.30</td>
<td>Concluding remarks</td>
<td>Ghassan Dbaibo</td>
</tr>
</tbody>
</table>
Novartis Vaccines Satellite Symposium & Panel Discussion

Tuesday, 21 May
13.00 – 14.30

Scientific Programme

Travelling with the next generation – NEWS on JE vaccination

Chair: Professor Robert Steffen

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and introduction</td>
<td>Professor Robert Steffen, University of Zurich, Switzerland</td>
</tr>
<tr>
<td>Introducing IXIARO® for paediatric use</td>
<td>Katrin Dubischar-Kastner, Intercell AG, Vienna, Austria</td>
</tr>
<tr>
<td>Do current JE vaccination recommendations match travellers’ risks?</td>
<td>Dr Tomas Jelinek, Berlin Center for Travel and Tropical Medicine, Berlin, Germany</td>
</tr>
<tr>
<td>Case reports and discussion</td>
<td>Professor Robert Steffen</td>
</tr>
<tr>
<td>Summary and close</td>
<td>Professor Robert Steffen</td>
</tr>
</tbody>
</table>
ISTM Committee and Group Meetings

ISTM Leadership Lounge and Secretariat Office, The Lisbon Room, Level 0, Room 0.7

Sunday, 19 May: 13.00-17.00
Monday, 20 May: 08.00-17.00
Tuesday, 21 May: 08.00-17.00

Wednesday, 22 May: 08.00-17.00
Thursday, 23 May: 08.00-12.00

Sunday, 19 May - All meetings held at the MECC.

WHO Consultation on International Travel and Health (ITH)
By Invitation Only; 10.00-14.00 in The Berlin/Copenhagen Rooms, Level 0, Rooms 0.2/0.3

ISTM Journal of Travel Medicine Editorial Board
By Invitation Only; 14.00-15.30 in Euro Room in the Euro Complex Centre

ISTM Publications Committee
By Invitation Only; 15.30-17.00 in Euro Room in the Euro Complex Centre

ISTM Nurses Reception
Open to All; 15.00-16.30 in The Brussels/Paris Rooms, Level 0, Rooms 04 and 05

ISTM Pharmacists Reception
Open to All; 15.00-16.30 in The Pressroom, Level 0, Room 0.11

Monday, 20 May - All meetings held at the MECC.

ISTM Examination Committee
By Invitation Only; 07.00-08.00 in The Rhine Room, Level 2, Room 2.8

ISTM Destination Communities Support Interest Group Council
By Invitation Only; 12.45-14.45 in The Meuse Room, Level 2, Room 2.7

ISTM Pediatric Interest Group Council
By Invitation Only; 12.45-14.45 in The Rhine Room, Level 0, Room 2.8

ISTM Psychological Health of Travellers Interest Group Council
By Invitation Only; 12.45-14.45 in The Euphrates Room, Level 2, Room 2.9

ISTM Destination Communities Support Interest Group General Assembly
Open to All; 18.30-19.15 in The Rome Room, Level 0, Room 0.8

ISTM Pediatric Interest Group General Assembly
Open to All; 18.30-19.15 in The Paris Room, Level 0, Room 0.5

ISTM Psychological Health of Travellers Interest Group General Assembly
Open to All; 18.30-19.15 in The Athens Room, Level 0, Room 0.9
Tuesday, 21 May - *All meetings held at the MECC.*

**ISTM Research and Awards Committee**  
By Invitation Only; 07.00-08.00 in The Meuse Room, Level 2, Room 2.7

**ISTM Migrant and Refugee Interest Group Council**  
By Invitation Only; 12.45-14.45 in The Euphrates Room, Level 2, Room 2.9

**ISTM Nursing Professional Group Council**  
By Invitation Only; 12.45-14.45 in The Rhine Room, Level 2, Room 2.8

**ISTM Pharmacist Professional Group Council**  
By Invitation Only; 12.45-14.45 in The Meuse Room, Level 2, Room 2.7

**ISTM Migrant and Refugee Interest Group General Assembly**  
Open to All; 18.30-19.15 in The Paris Room, Level 0, Room 0.5

**ISTM Nursing Professional Group General Assembly**  
Open to all Nurses; 18.30-19.15 in The Rome Room, Level 0, Room 0.8

**ISTM Pharmacist Professional Group General Assembly**  
Open to all Pharmacists; 18.30-19.15 in The Athens Room, Level 0, Room 0.9

Wednesday, 22 May - *All meetings held at the MECC.*

**CISTM13 Scientific Program Committee**  
By Invitation Only; 07.00-08.00 in The Rhine Room, Level 2, Room 2.8

**ISTM Continuing Professional Development Committee**  
By Invitation Only; 12.45-14.45 in The Meuse Room, Level 2, Room 2.7

**ISTM Professional Education Committee**  
By Invitation Only; 12.45-14.45 in The Rhine Room, Level 2, Room 2.8

**ISTM GeoSentinel/EuroTravNet/CanTravNet Network Members**  
Open to All; 13.15-14.30 in The Rome Room, Level 0, Room 0.8

**ISTM Membership Assembly followed by Cocktail Reception**  
Open to All; 17.15-19.30 in Auditorium 2

**Related Society Meetings** - *All meetings held at the MECC.*

**Asia Pacific Travel Health Society and Scientific Committee Meeting**  
By Invitation Only; Tuesday, 21 May, 07.00-09.00 in The Euphrates Room, Level 2, Room 2.9

**NECTM Steering and Scientific Committee**  
By Invitation Only; Monday, 20 May, 18.30-20.00 in The Rhine Room, Level 2, Room 2.8
Exhibition

The Exhibits, Posters, and Tea/Coffee Breaks are located on the main level of the MECC in the Expo Foyer from Monday, 20 May through Wednesday, 22 May. The MECC will provide special food outlets to easily purchase lunch within the centre.

Exhibition Schedule:

Sunday, 19 May 2013
Welcome Reception, 18.00-20.00

Monday, 20 May 2013
Exhibits and Posters 10.30-17.00
Tea/Coffee Breaks 10.30-11.15 and 16.15-17.00
Lunch Break 12.45-14.45

Tuesday, 21 May 2013
Exhibits and Posters 10.30-17.00
Tea/Coffee Breaks 10.30-11.15 and 16.15-17.00
Poster Tours 10.30-11.15 and 16.15-17.00
Lunch Break 12.45-14.45

Wednesday, 22 May 2013
Exhibits 10.30-17.15
Coffee Breaks 10.30-11.15 and 16.15-17.15
Lunch Break 12.45-14.45
Poster Session/Authors in Attendance 16.15 - 17.15
## Exhibitor List with Exhibition Locations

<table>
<thead>
<tr>
<th>Stand 1:</th>
<th>GlaxoSmithKline Vaccines registered as GlaxoSmithKline Biologicals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stand 2:</td>
<td>International Society of Travel Medicine</td>
</tr>
<tr>
<td>Stand 3:</td>
<td>Crucell</td>
</tr>
<tr>
<td>Stand 4:</td>
<td>Sigma-Tau S.p.A.</td>
</tr>
<tr>
<td>Stand 5:</td>
<td>inFact UK Ltd</td>
</tr>
<tr>
<td>Stand 6:</td>
<td>Sitata Inc.</td>
</tr>
<tr>
<td>Stand 7:</td>
<td>Novartis Vaccines &amp; Diagnostics, Inc.</td>
</tr>
<tr>
<td>Stand 8:</td>
<td>tropimed*</td>
</tr>
<tr>
<td>Stand 9:</td>
<td>Oxford University Press</td>
</tr>
<tr>
<td>Stand 10:</td>
<td>Bimuno*</td>
</tr>
<tr>
<td>Stand 11:</td>
<td>Sanofi Pasteur MSD</td>
</tr>
<tr>
<td>Stand 12:</td>
<td>Centers for Disease Control &amp; Prevention</td>
</tr>
<tr>
<td>Stand 13:</td>
<td>NECTM</td>
</tr>
<tr>
<td>Stand 14:</td>
<td>Royal College of Physicians and Surgeons of Glasgow</td>
</tr>
<tr>
<td>Stand 15:</td>
<td>International SOS</td>
</tr>
<tr>
<td>Stand 16:</td>
<td>South African Society of Travel Medicine (SASTM)</td>
</tr>
<tr>
<td>Stand 17:</td>
<td>Shoreland, Inc</td>
</tr>
</tbody>
</table>

In the exhibition there is a special area set up for materials about the Travel Medicine Regional Meetings that will be taking place in 2014.

There is also a Free Literature Area in the exhibition where not-for-profit organizations and societies are invited to place their meeting promotional literature.
Exhibition Floor Plan
Exhibitor Information

GlaxoSmithKline Vaccines registered as GlaxoSmithKline Biologicals
Rue de l’Institut 89, 1330 Rixensart, Belgium
Tel: +32 (0)10 85 51 11
Website: www.gsk.com
GlaxoSmithKline is one of the world’s leading vaccine companies and a leader in innovation. The company is active in vaccine research, development and production with over 30 vaccines approved and 18 more in development - both in the prophylactic and therapeutic fields. For further information, please visit www.gsk.com

Novartis Vaccines & Diagnostics, Inc.
350 Massachusetts Avenue, Cambridge, MA 02139, USA
Contact Person: Elizabeth Power
Tel: +1 617 871 7000
Email: nvd.communications@novartis.com
Website: www.novartisvaccines.com
“Caring Begins with Prevention”
At Novartis Vaccines and Diagnostics, we believe that caring for patients begins with protecting individuals and societies from infection in the first place. Our innovative vaccines and diagnostics tools are designed to prevent the spread of life-threatening diseases in order to protect vulnerable populations and keep healthy people healthy.

Bimuno®
5 Canon Harnett Court, Wolverton Mill, Milton Keynes MK12 5NF
Contact Person: Christopher Chrysanthou
Tel: +44 (0)1908 577850
Email: Christopher.chrysanthou@clasaco.com
Website: www.bimuno.com
Clasado researches and develops prebiotics and markets them as scientifically proven gut health supplements, under the brand name Bimuno®. Bimuno® is the only 2nd generation prebiotic and offers additional selectivity and functionality over probiotics and other prebiotics. Bimuno® TRAVELAID was developed to provide nutritional support for holidaymakers and business travellers. www.bimuno.com
The CDC Travelers’ Health Branch works to reduce illness and injury in U.S. residents traveling internationally or living abroad. The branch provides travel health advice, including vaccine recommendations and requirements, to international travelers and the health care providers who advise them. The branch produces *CDC Health Information for International Travel*, commonly referred to as the “Yellow Book,” the definitive U.S. travel medicine reference for clinicians advising patients before and after travel and is a renowned reference throughout the world. CDC’s Travelers’ Health website (www.cdc.gov/travel) provides outbreak updates and travel notices, travel-related disease information, and destination-specific recommendations for travelers and their health care providers. The website contains information for specific groups of travelers, such as children, study-abroad students, humanitarian and emergency response workers, and special needs travelers. Additional resources include podcasts, presentations, and a registry of U.S. clinics that provide yellow fever vaccine.

**Crucell**

Archimedesweg 4-6, 2333 CN Leiden, The Netherlands  
Contact Person: Jeannette Jager van Dijk  
**Tel:** +31 (0)71 519 9100  
**Email:** ra-crxnl-info@its.jnj.com  
**Website:** www.cruell.com  

Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Our portfolio includes a fully liquid pentavalent vaccine, an aluminum-free hepatitis A vaccine, oral vaccines against typhoid and cholera, and a virosomal adjuvanted vaccine against influenza. Crucell is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
inFact UK Ltd
Unit 13, Mercury Quays, Ashley Lane, Shipley, BD17 7DB, UK
Contact Person: Dr Chakib Kara-Zaïtri
Tel: +44 (0) 1274 585 365
Email: Chakib@in-Fact.com
Website: www.in-fact.com

inFact UK proudly announce HPTravel - A secure web-based software suite for Travel Health and Vaccination, developed with travel health experts. HPTravel consists of five integrated modules: Online Booking, Call Centre, Reception, Clinical and Administration. inFact UK have 14 years experience in developing software in Public Health. Please visit http://HPTravelinfo.in-fact.com.

International SOS
331 Northbridge Road, #17-00, Odeon Towers, 188720, Singapore
Contact Person: Diane Hutchinson
Tel: +65 6330 9832
Email: Diane.HUTCHINSON@internationalsos.com
Website: www.internationalsos.com

International SOS is the world's leading provider of medical assistance, international healthcare and security services. Our expertise enables organisations to manage the health risks facing their international travellers and global workforces. We offer our medical professionals the opportunity to develop an exciting international career whilst delivering international standards of healthcare.
Northern European Conference on Travel Medicine (NECTM)

Kongress & Kultur AS, P.O. Boks 947 Sentrum, N-5008 Bergen, Norway
Contact Person: Pål Voltersvik
Tel: +47 901 05 488
Email: pal.voltersvik@gades.uib.no
Website: www.nectm.com

NECTM was founded in November 2003 and the 1st NECTM was held in Edinburgh in May 2006. Experience from the biannual Scandinavian conferences since 1998 (SFTM) has been useful for NECTM as a regional conference. Since, 3 biannual conferences have been arranged in Helsinki (2008), Hamburg (2010) and Dublin (2012) with 800 – 1000 participants from European counties and also from overseas. Each conference has its own focus; thus the next NECTM in Bergen, Norway, in 2014 should be of particular interest for the delegates to this CISTM as well!

Oxford University Press

Great Clarendon Street, Oxford OX2 6DP, UK
Contact Person: Beth McAllister
Tel: +44 (0) 1865 556767
Email: beth.mcallister@oup.com
Website: www.global.oup.com

Oxford University Press publishes some of the most respected medical content in the world, including titles such as CDC Health Information for International Travel, Travellers’ Health: How to stay healthy abroad and the Oxford Textbook of Medicine: Infection. Visit our stand to browse books and enjoy an exclusive conference discount.

Royal College of Physicians and Surgeons of Glasgow

232-242 St Vincent Street, Glasgow, G25RJ, UK
Contact Person: Muir Brown
Tel: +44 (0) 141 221 6072
Email: muir.brown@rcpsg.ac.uk
Website: www.rcpsg.ac.uk

The Royal College of Physicians and Surgeons of Glasgow is the only multidisciplinary Royal College in the UK and home to the Faculty of Travel Medicine. We provide high quality education, training, professional development, examinations and assessment to more than 10,000 members worldwide, including medical and non-medical specialists in travel medicine.
Sanofi Pasteur MSD
Sanofi Pasteur MSD The Netherlands, Postbus 396, 2130 AJ, Hoofddorp
Contact Person: Drs. Chris de Jong
Tel: +31 23 567 9600
Email: servicenl@spmsd.com
Website: www.spmsd.com
Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the vaccine division of Sanofi, and Merck (known as MSD outside the US and Canada). Sanofi Pasteur MSD is headquartered in Lyon, France. At Sanofi Pasteur MSD, we believe that vaccination is a way to move Europe forward towards a future where people can stay ahead of disease. Vaccines are our passion because we know that they are the key to a world in better health.

Shoreland, Inc
P.O. Box 13795, Milwaukee, WI 53213-0795, USA
Contact Person: Bridget Mulgrew
Tel: +1 414-290-1900
Email: sales@shoreland.com
Website: www.shoreland.com
Shoreland Travax® is a web-based resource meeting the global health and safety information needs of travel medicine practitioners and medical managers. Shoreland editors and medical advisors turn up-to-date data into the information you require to make the care and counseling decisions you face with your patients and your personnel abroad.

Sigma-Tau S.p.A.
Head Office & Research Centre: Via Pontina Km. 30,400, - 00040 Pomezia (Rome), Italy.
Contact Person: Antoinette Celli
Tel: +39 (0) 6 9139 3704 - 3432
Email: antoinette.celli@sigma-tau.it
Website: www.sigma-tau.it
Sigma-Tau is a leading, all Italian capital, International pharmaceutical Group. Sigma-Tau R&D is focused on the following therapeutic areas: Rare and Neglected Diseases, Oncology, Immuno-oncology. Recently Sigma-Tau, in partnership with the non-profit organization Medicines for Malaria Venture (MMV) has developed an antimalarial product available in Europe, Cambodia and Ghana.
Sitata Inc.
36 Cumberland Dr. 2nd Floor, Mississauga, On, L5G 3M8, Canada
Contact Person: Adam St. John
Tel: +1 (888) 997-5279
email: astjohn@sitata.com or support@sitata.com
website: www.sitata.com
Advance your travel medicine practice with a hassle-free, web-based app to save you time and protect your clients. With Sitata, you can customize & store your medical recommendations online for each traveller's personal itinerary, and health & safety alerts are delivered to travellers in real-time to keep them informed while abroad.

South African Society of Travel Medicine (SASTM)
27 Linksfield Road Dunvegan,
Edenvale 1609 Gauteng South Africa
Contact: Mrs Marion Blewett
Tel: +27 11 025 3297
Email: admin@sastm.org.za
Website: www.sastm.org.za
The SASTM’s Mission is to guide the profession in all aspects relating to the practice of travel medicine, liaise with the travel industry, consult with relevant authorities, advise the public and collaborate nationally and internationally on all aspects relating to Travel Medicine.

tropimed®
Rue Pedro Meylan 7 - P.O. Box 142 CH-1211 Geneva 17,
Switzerland
Contact Person: Inauen Manuela
Tel: +41 22 718 96 40
Email: custserv@tropimed.com
Website: www.tropimed.com
travel medicine expert program, updated daily since 1992
tropimed® is for health professionals and those providing travel medical advice. Provides specific information on 231 destinations, epidemiological maps and much additional information as needed.
tropimed® is available via the Internet, in standalone versions for Windows® or Mac® computers or network servers.
The Professional and Education Committee (PEC) of ISTM has developed an initiative entitled "Expert Opinion" as an educational vignette. New scenarios and opinions are presented regularly on the ISTM website at www.ISTM.org.

Expert Opinion presents a pre- or post-travel quandary that is answered by an invited ISTM member with expertise in the topic discussed. The international membership includes varied clinical approaches, and the expert is offering only an opinion on a particular subject and should not be taken as a directive for all patients or cases. The PEC encourages ISTM members to discuss additional aspects relating to the scenario on the TravelMed Listserv. The cases and Expert Opinions are retained on the site so that visitors have the ability to review previous scenarios.

2013
- **Case 1** (Poh Lian Lim, Singapore) — Advice on Dengue fever for an American student going to live two years in Asia

2012
- **Case 1** (Martin Haditsch, Leonding, Austria and Hannover, Germany) — TBE Advice for Honeymooners travelling to southern Austria, Switzerland and Germany
- **Case 2** (Christopher van Tilburg, United States of America) — Advice to adolescent traveler for sports competition at high altitude

2011
- **Case 1** (Pierre van Damme, Belgium) — Hepatitis A and B advice for a student travelling to India
- **Case 2** (Dale Carroll, USA) — YF vaccination for a pregnant woman traveling to Ivory Coast
- **Case 3** (Stephen Toovey, South Africa) — Malaria risk of a Swiss Traveler to Hong Kong, Thailand and India

2010
- **Case 1** (Hilary Simons, United Kingdom) — Spacing of live vaccines in a traveller to Ghana
- **Case 2** (David Freedman, United States of America) — Travel advice for a trip to Southern Africa

2009
- **Case 1** (Frank Bia, United States of America) — Follow-up positive TB skin tests
- **Case 2** (Joel E. Gallant, United States of America) — Occupational exposure to HIV

2008
- **Case 1** (Philippe Gautret, France) — Rabies post-exposure case from China
- **Case 2** (Buddha Basnyat, Nepal) — Enteric fever in a Danish expatriate to Nepal
- **Case 3** (Karin Leder, Australia) — Influenza in travellers

Please note the expert is offering only an opinion on a particular subject and should not be taken as a directive for all patients or cases. To access the information, please go to the ISTM Website at www.ISTM.org and select the link to Expert Opinions under Member News and Resources right on the home page.

We hope you find this ISTM Professional Education Committee initiative helpful in your practice. The cases are all available directly from the ISTM website at www.ISTM.org.
This 158-slide PowerPoint slide set has been recently updated and has doubled in size since the 2008 version to include enhanced materials on special needs travelers (children, pregnant women and compromised hosts), and entirely new material on common post-travel syndromes and specific infections. The presentation is suitable for lecturing to both healthcare professionals and lay groups. Slides are grouped by subject area (e.g., Risk Assessment, Vaccines, Malaria, Travelers’ Diarrhea, Special Needs Travelers, Post-Travel Syndromes) for easy customization of lectures. Material and teaching points are international in scope, allowing the presenter to elaborate on specific local dosing and availability issues.

Authors of the slideset are Eric Caumes, MD, Professor of Infectious and Tropical Diseases at the Hôpital Pitié-Salpêtrière in Paris, France and Bradley A. Connor, MD, Director of the New York Center for Travel and Tropical Medicine and Clinical Associate Professor of Medicine at Weill Medical College of Cornell University, New York, United States.

The slide set was peer-reviewed by key opinion leaders from Australia, France, Germany, Israel, Switzerland, South Africa, the United Kingdom and the United States of America, ensuring the international relevance and applicability of the content.

In an effort to expand the reach of its educational offerings, ISTM established a Distance Learning Program. With more than 60 sessions currently available, a range of relevant topics are accessible to all travel medicine practitioners, with both introductory and more advanced content.

Modules offer both video with synchronized slides, and audio with synchronized slides. Individual sessions range from 30 minutes to four hours. These modules can be ordered individually or with volume discounts, and are available for viewing over the internet for six months after purchasing.

The following are a few of the many titles or subject areas currently available:
  • Dengue: Into the Future
  • Emergencies in Travel Medicine
  • Preparation of Last Minute Travelers
  • Travelers’ Diarrhea
  • Malaria Prevention
  • Rabies
  • Preparing Your Patients for Mass Gatherings
  • High Risk and Special Needs Travelers
  • Special Populations: Business, Long-stay, and Visiting Friends or Relatives Travelers
GSK invites you to a Satellite symposium on **Monday 20th May** (13.00 – 14.30) entitled *Meningococcal Vaccination amongst the travel population*

GSK is committed to the prevention of life-threatening diseases and to the improvement of public health across the globe.

Registered as GlaxoSmithKline Biologicals SA
Rue de l’Institut, 89 BE-1330 Rixensart. RPM Nivelles BE 0440.872.918
www.gsk.com